¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/3 ¤W¤È 10:06:00
²Ä 6627 ½g¦^À³
|
ASLAN ªº Æ[°·®É¨è
ASLAN ±NÀò±o1200 ¸U¬ü¤¸ªº¹w¥I´Ú¡A¨Ã¦b¹F¨ìTREK-AD 2b ´Á¸ÕÅç¼Æ¾ÚŪ¥X©MÁ{§É¬ã¨s³ø§i ¥æ¥Iªº¬Y¨Ç¹w¥ý°Ó©w±ø¥ó«á¡A¦³¸ê®æ±qZenyaku Àò±oÃB¥~ªº300 ¸U¬ü¤¸¡A³Ì°ª¥i¹F2950¸U¬ü¤¸ ¶}µo¨½µ{¸O©M°ª¹F 9,400 ¸U¬ü¤¸ªº°Ó·~¨½µ{¸O¡C Zenyaku ±N®Ú¾Úeblasakimabªº²b¾P°âÃB ¦V ASLAN ¤ä¥I¨â¦ì¼Æªº¯S³\Åv¨Ï¥Î¶O( Roalty)¡A¦Ê¤À¤ñ³Ì°ª¥i¹F 20%¡C®Ú¾Ú³\¥i¨óijªº±ø´Ú¡A Zenyaku ±Nt³deblasakimab¦b¤é¥»ªº©Ò¦³¶}µo©M°Ó·~¤Æ¬¡°Ê¡C Zenyakup¹º©ó2024¦~¤W¥b¦~ ¦b¤é¥»±Ò°Êeblasakimabªº¤@´Á¬ã¨s¡C ( ¤é¥»ÃÄ«~¥«³õ¦û¤ñ¦Ê¤À¤§5 ¬ü¼Ú¤¤¦û¤ñ³Ì°ª )
¨Ì¾Ú¤W¤å Ó¤Hµû½× : ÁÙ¥¼°Ó·~¤Æ 9,400 ¸U¬ü¤¸ªº°Ó·~¨½µ{¸O¡C Zenyaku ±N®Ú¾Úeblasakimabªº²b¾P°âÃB ¦V ASLAN ¤ä¥I¨â¦ì¼Æªº¯S³\Åv¨Ï¥Î¶O( Roalty)¡A¦Ê¤À¤ñ³Ì°ª¥i¹F 20% ³oÓ³¡¤À¥Ø«eÁÙ®³§G¤£¨ì
1 Zenyakup¹º©ó2024¦~¤W¥b¦~¦b¤é¥»±Ò°Êeblasakimabªº¤@´Á¬ã¨s 2 ¦b¹F¨ìTREK-AD 2b ´Á¸ÕÅç¼Æ¾ÚŪ¥X©MÁ{§É¬ã¨s³ø§i¥æ¥Iªº¬Y¨Ç¹w¥ý°Ó©w±ø¥ó«á¡A ¦³¸ê®æ±qZenyaku Àò±oÃB¥~ªº300 ¸U¬ü¤¸¡A³Ì°ª¥i¹F2950¸U¬ü¤¸¶}µo¨½µ{¸O 3 TREK-AD 2b±Ò°Ê¤T´ÁÁ{§É®É ¦³¾÷·|®³¨ìÃB¥~ªº300 ¸U¬ü¤¸»P2950¸U¬ü¤¸¶}µo¨½µ{¸O¤¤ªº³¡¥÷¸êª÷
4 ¦X²z±À½×n®³¨ì¶}µo¨½µ{¸O¤¤ªº³¡¥÷¸êª÷¤½¥q¥²»Ý¦b6¤ë3¤é«e±Ò°Ê¤T´ÁÁ{§É
5 ¤]¦³¥i¯à¦pªoºj©Ò¨¥:¦pªG¯uªº¯à©µ´Á¡A¥NªíASLNµ¹¤FNasdaq¥i¦æ©Ê«Ü°ªªºp¹º (©µ´Á180¤Ñ)
6 ¥i¦æ©Ê«Ü°ªªºp¹º·|¬O»PZenyakuªº¥ý«e¬ù©w, ªñ´Á¦A¬ù©w ©Î¬O¥t¦³¦X§@¹ï¶H ???
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
§¹¾ãª© ASLAN Pharmaceuticals »P Zenyaku Kogyo µ¦²¤©Ê±ÂÅv¨óij:
ASLAN Pharmaceuticals »P Zenyaku Kogyo ´N Eblasakimab ¦b¤é¥»ªº¶}µo©M°Ó·~¤Æ ¹F¦¨µ¦²¤©Ê±ÂÅv¨óij 2023 ¦~ 6 ¤ë 22 ¤é
ASLAN ±NÀò±o°ª¹F 1500 ¸U¬ü¤¸ªº¹w¥I´Ú©Mªñ´Á¥I´Ú¡A¥H¤Î°ò©ó¶}µo©M°Ó·~¨½µ{¸OªºÃB¥~ °ª¹F 1.235 »õ¬ü¤¸ªºÃB¥~¸êª÷¡A¥H¤Î³Ì°ª 20% ªº¤À¼h¾P°â¯S³\Åv¨Ï¥Î¶O( Roalty)
¤é¥»»â¥ýªº¥Ö½§¯f¾Ç©M¸~½F¾Ç»sÃĤ½¥q Zenyaku Kogyo p¹º©ó 2024 ¦~¤W¥b¦~¦b¤é¥»±Ò°Ê eblasakimabªº 1 ´Á¬ã¨sASLAN°w¹ï¤¤««× AD ±wªÌ¶i¦æªºeblasakimab¥þ²y TREK-AD 2b ´Á ¬ã¨sªº¥Dn¼Æ¾Ú¹wp±N©ó 2023 ¦~ 7 ¤ëªìµo¥¬
¥[¦{¸t°¨¤N¡B·s¥[©Y©MªF¨Ê¡A2023 ¦~6 ¤ë22 ¤é¡]Àô²y³q°TªÀ¡^¡XASLAN Pharmaceuticals ¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A P¤O©ó¶}µo³Ð·sÀøªk¨Ó§ïÅܤH̪º¥Í¬¡±wªÌ©M¤é¥»»â¥ý»sÃĤ½¥qZenyaku Kogyo Co., Ltd. ¡]¡§Zenyaku¡¨¡^¡]¨p¤H±±ªÑZenyaku Holdings Co., Ltd.¡]¡§Zenyaku Holdings¡¨¡^ªº¤l¤½¥q¡^ ¤µ¤Ñ«Å¥¬Ã±¸p¾Ô²¤³\¥i¨óij¡A±Â¤©Zenyaku ¿W®aÅv§Q¦b¤é¥»²§¦ì©Ê¥Ö½§ª¢¡]AD¡^©M©Ò¦³¨ä¥L¾AÀ³¯gªºeblasakimab ¡C
ASLAN ±NÀò±o1200 ¸U¬ü¤¸ªº¹w¥I´Ú¡A¨Ã¦b¹F¨ìTREK-AD 2b ´Á¸ÕÅç¼Æ¾ÚŪ¥X©MÁ{§É¬ã¨s³ø§i ¥æ¥Iªº¬Y¨Ç¹w¥ý°Ó©w±ø¥ó«á¡A¦³¸ê®æ±qZenyaku Àò±oÃB¥~ªº300 ¸U¬ü¤¸¡A³Ì°ª¥i¹F2950¸U¬ü¤¸ ¶}µo¨½µ{¸O©M°ª¹F 9,400 ¸U¬ü¤¸ªº°Ó·~¨½µ{¸O¡C Zenyaku ±N®Ú¾Úeblasakimabªº²b¾P°âÃB ¦V ASLAN ¤ä¥I¨â¦ì¼Æªº¯S³\Åv¨Ï¥Î¶O¡A¦Ê¤À¤ñ³Ì°ª¥i¹F 20%¡C®Ú¾Ú³\¥i¨óijªº±ø´Ú¡AZenyaku ±Nt³deblasakimab¦b¤é¥»ªº©Ò¦³¶}µo©M°Ó·~¤Æ¬¡°Ê¡C Zenyakup¹º©ó2024¦~¤W¥b¦~¦b¤é¥»±Ò°Ê eblasakimabªº¤@´Á¬ã¨s¡C
Zenyaku ¦b¤é¥»¥Ö½§¯f¾Ç©M§K¬Ì¾Ç¾AÀ³¯g¤è±¾Ö¦³Â×´Iªº²£«~¶}µo¡BºÊºÞ©M¦æ¾P±M·~ª¾ÃÑ¡C §@¬°¥þ²y»â¥ý»sÃĤ½¥qªºªø´Á¦X§@¹Ù¦ñ¡AZenyaku¦b¤é¥»¥«³õ¾P°â Rituxan ®¡]§Q§´©õ³æ§Ü¡^¡A ¨Ã¦b¤é¥»¶i¦æ©Ò¦³Á{§É¶}µo¡C Zenyaku ¤w¦¨¥\Àò±o¤é¥»ºÊºÞ¾÷ºc§åã Rituxan ®ªº¥t¥~ 11 ºØ¾AÀ³¯g¡A¥]¬A¦hºØ¸~½F¾Ç©M¥Ö½§¯f¾Ç¾AÀ³¯g¡A¨ä¤¤ 7 ºØ¬O¤é¥»¥«³õ¿W¦³ªº¡C
¡u§ÚÌ«D±`°ª¿³»P Zenyaku ¦X§@¡AZenyaku ¬O¤@®a»â¥ýªº¤é¥»»sÃĤ½¥q¡A¾Ö¦³¨ô¶VªºÁ{§É©M¥Í©R¶g´Á ºÞ²z±M·~ª¾ÃÑ¡C Zenyaku ¦b¶}µo·s«¬¥Íª«»s¾¯¡BÀò±oºÊºÞ³¡ªù§åã¥H¤Î¦b¤é¥»¦¨¥\°Ó·~¤Æ¥Ö½§¯fÀøªk ¤è±«Ø¥ß¤F¦¨¥\ªº°O¿ý¡A¡vASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤h»¡¡C¡u¦b¤é¥»¡AAD ªºt¾á«Ü«¡A¦Ó¥BÁÙ¦b¤£Â_¼W¥[¡X¡X¦³ 500 ¸U¤H±w¦³³oºØ¯e¯f1¡AÁÙ¦³¼Æ¦Ê¸U¤H±w¦³¨ä¥L 2 «¬¯e¯f¡C ÀHµÛ§Ú̦b¥þ²y½d³ò¤º±µªñeblasakimabªº«á´Á¶}µo¡A¹ï§Ų́ӻ¡¡A§ä¨ì¹³ Zenyaku ³o¼Ëªº¦X§@¹Ù¦ñ «D±`«n¡A¥LÌ¥i¥H§Q¥Î¨ä¸gÅç¨Ó¥[³teblasakimab¦b¤é¥»ªº¶}µo¡C
Zenyaku Kogyo Á`µôÝ°õ¦æªø¾ô¥»¯E¤@ (Koichi Hashimoto)ªí¥Ü¡G ¡uÀHµÛ¤é¥»¤¤«×¦Ü««×AD ªº¥Í¬¡t¾á«ùÄò¥[«¡AÂå¥Í©M±wªÌ¹ï§ó¨ã³Ð·s¡B¦³®Ä©M«K§QªºªvÀø¤èªkªº»Ý¨D¤£Â_¼W¥[¡C ¡¨ ¡C ¡u§ÚÌ«Ü°ª¿³»P ASLAN ¦X§@¡AÂX¤j§Ú̪º¥Ö½§¬ì²£«~²Õ¦X¡Aeblasakimab¿W¯Sªº§@¥Î¾÷¨î¥H¤Î¦w¥þ¡B ¦³®Ä©M¤è«K¦aªvÀø¤¤«×¦Ü««× AD ªº¼ç¤O¡A¥Nªí¤F§Ú̪º«n©M¾Ô²¤©Ê¸É¥R¡CºÞ¹D¡C°ò©ó¨´¤µ¬°¤î ²£¥Íªº¿n·¥¼Æ¾Ú¡A§Ú̬۫Heblasakimab¦³¼ç¤O¦¨¬°¤é¥»¤@¬yªº AD ®t²§¤ÆÀøªk¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/2 ¤U¤È 11:32:43
²Ä 6626 ½g¦^À³
|
¥h¦~¤»¤ë ASLAN Pharmaceuticals »P Zenyaku Kogyo ´N Eblasakimab ¦b¤é¥»ªº¶}µo©M°Ó·~¤Æ¹F¦¨µ¦²¤©Ê±ÂÅv¨óij
±ø¥ó¦p¤U
ASLAN ±NÀò±o°ª¹F 1500 ¸U¬ü¤¸ªº¹w¥I´Ú©Mªñ´Á¥I´Ú¡A¥H¤Î°ò©ó¶}µo©M°Ó·~¨½µ{¸OªºÃB¥~°ª¹F 1.235 »õ¬ü¤¸ªºÃB¥~¸êª÷¡A¥H¤Î³Ì°ª 20% ªº¤À¼h¾P°â¯S³\Åv¨Ï¥Î¶O
¤é¥»»â¥ýªº¥Ö½§¯f¾Ç©M¸~½F¾Ç»sÃĤ½¥q Zenyaku Kogyo p¹º©ó 2024 ¦~¤W¥b¦~¦b¤é¥»±Ò°Êeblasakimabªº 1 ´Á¬ã¨s
µû½× ¤é¥»³o®a¤½¥q·|ÂX¤j¦X§@®×¡A À³¸Ó¬O¹ïÁ{§É¼Æ¾Úº¡·N¤~·|¦A¥X¸êÂX¤j¬ã¨s¦X§@¡A¨Ãû£°Ê£¸´ÁÁ{§É¡A«á±ÁÙ¦³1.235»õ¬ü¤¸ªº¶}µo»P°Ó·~®Èµ{ª÷nµ¹¤½¥q¡A¦b¤é¥»¾P°âÃB¦Ê¤À¤§20ªº Roalty nµ¹¤½¥q¡A¤»¤ë¤T¤é«e¦p¯à¨ú±oÃB¥~¸êª÷¡A¤½¥q¦M¾÷´N¸Ñ°£¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/5/2 ¤U¤È 10:24:12
²Ä 6625 ½g¦^À³
|
2023 ¦~ 6 ¤ë»P¤é¥»Zenyaku ¶}µo©M°Ó·~¤Æeblasakimabªº°Ó·~¨óij±NÂX¤j¦X§@ ( ³o¶µ¦X§@±N¥Ñ Zenyaku ¥X¸ê)
ASLAN Pharmaceuticals «Å¥¬ÂX¤j»P Zenyaku ªº¦X§@( ¤é¥»)¡A¥H¬ã¨s Eblasakimab »P ¨ä¥L¥Íª«»s¾¯¬Û¤ñ¸ûI«áªº¥Íª«¾Ç®t²§®ÄÀ³
·sªº¬ã¨s¦X§@±N±´¯Áeblasakimab ªº§@¥Î¾÷¨î»P°w¹ï²§¦ì©Ê¥Ö½§ª¢ (AD)¡Bdupilumab©Mlebrikizumab ªº¥Íª«Àøªk¤§¶¡ªº®t²§¡C
³o¨Çµo²{±N¥[²`¹ï³Ìªñµo²{ªº¥Íª«¾Ç°ò¦ªº²z¸Ñ¡A§Y¤@¨Ç AD ±wªÌ§Y¨Ï¹ï dupilumab ¤ÏÀ³¤£¨¬¡A ¤]¥i¯à¹ïeblasakimab²£¥Í¤ÏÀ³¡C
¦X§@ªº²Ä¤@³¡¤À±N«ÂI©ñ¦b¨üÅé¥Íª«¾Ç©M°Ê¤O¾Ç¡A¥H¬ã¨seblasakimab¤À¤Æ¼ç¤Oªº²ÓM©M¤À¤l°ò¦¡C ³o¶µ¤u§@±N¥Ñ Zenyaku ¸ê§U¡C
¥[¦{¸t°¨¤N©M·s¥[©Y¡A2024 ¦~5 ¤ë2 ¤é¡]Àô²y³q°TªÀ¡^- ASLAN Pharmaceuticals ¡]¯Ç´µ¹F§J¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo ³Ð·sÀøªk¨Ó§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¥¦»P¨ä¦X§@¹Ù¦ñ Zenyaku Kogyo Co., Ltd. (Zenyaku) ñ¸p¤F¤@¶µ·sªº¬ã¨s¦X§@¨óij¡A¬°¤@¨t¦C¬ã¨s¶µ¥Ø«Ø¥ß®Ø¬[¡A·sªº¬ã¨s¦X§@±N±´¯Áeblasakimab ªº§@¥Î¾÷¨î»P°w¹ï²§¦ì©Ê¥Ö½§ª¢ (AD)¡Bdupilumab©Mlebrikizumab ªº¥Íª«Àøªk¤§¶¡ªº®t²§
¦b¥ý«eµoªíªº AD ±wªÌ§K¬Ì²ÓM©M¥Ö½§¬¡À˪ºÂà¤Æ¼Æ¾Ú1¤¤¡A¥ÎeblasakimabªýÂ_ IL-13 ¨üÅé (IL-13R)¦ü¥G¤ñªýÂ_IL-4 ¨üÅé(IL-4R) §ó¯à¦³®Ä¤U½Õµoª¢¼Ð°O¡C®Ú¾Ú·sªº¬ã¨s¦X§@¡A ASLAN©MZenyaku±N¶i¦æ¦X§@¬ã¨s¡A±´¯ÁIL-13©MIL-4¨üÅ骺¥Íª«¾Ç¡A¥]¬A¥Íª«»s¾¯ eblasakimab¡Bdupilumab©Mlebrikizumab¹ï¨CÓ¨üÅé¨È°òªº¼vÅT¡C
³o¶µ¬ã¨s¦X§@ªºµ²ªG±N¶i¤@¨B²`¤J¤F¸Ñ¹v¦V IL-13R »P IL-4R ªº®t²§¤Æ¨üÅé¥Íª«¾Ç¡C ³o¨Ç¬ã¨sÁÙ¥i¥H¸ÑÄÀ¦´ÁÁ{§É¬ã¨s¤¤¦beblasakimabªvÀø´Áµ²§ô«áÆ[¹î¨ìªº¯e¯fÄY« µ{«×¥Íª«¼Ð°O¡]¨Ò¦p TARC¡^ªºªø´Á§í¨î¡C³o¶µ·s¨óijÂX®i¤F ASLAN »P Zenyaku ©ó 2023 ¦~ 6 ¤ëñ¸pªºÃö©ó¦b¤é¥»¶}µo©M°Ó·~¤Æeblasakimabªº°Ó·~¨óij¡C
¡uEblasakimab¥i¯à¦¨¬°ªvÀø¶V¨Ó¶V¦h AD ±wªÌªº«n·sÀøªk¡A§ÚÌ«Ü°ª¿³ÂX¤j »P ASLAN ªº¦X§@¡A³z¹L§Q¥Î§Ú̪º¦yºÝ¬ã¨s³]¬I¡A¶i¤@¨B¤F¸ÑEblasakimab»P ¨ä¥L¥Íª«»s¾¯ªº°Ï§OI«áªº¬ì¾Çì²z¡C°ò©ó ASLAN ¨´¤µ¬°¤î²£¥Íªº±j¦³¤OªºÂà¤Æ ©MÁ{§É¼Æ¾Ú¡A§Ú̬۫Heblasakimab¨ã¦³¿W¯Sªº§@¥Î¾÷¨î¡A¥i¥H¬°±wªÌ´£¨Ñ¦w¥þ¡B ¦³®Ä©M¤è«Kªº AD ªvÀø·s¿ï¾Ü
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/4/27 ¤W¤È 11:43:00
²Ä 6624 ½g¦^À³
|
³o¤½¥q©{¦p¶BÄF¶°¹Î¡A
¥Xªº³ø§i½Ö«H¡A ¨S±Ï¤F¡A ªü¤TCEO¡A ·Ç³Æ¤U¥« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/27 ¤W¤È 09:20:47
²Ä 6623 ½g¦^À³
|
1.¥Ø«e¹ïASLN¨Ó»¡¡A³Ì«æ¢ªº¨Æ±¡¬O²bȤ£¨¬¡AªÑ²¼¦XªÑ¥u¯à´£¤ÉªÑ»ù¨ÃµLªk´£¤É²bÈ¡A©Ò¥H¥u¦³¨ú±o¸êª÷¤~¯à¸Ñ¨M²bÈ°ÝÃD¡C 2.³o¦¸trek-dx¤½§iªº¼Æ¾Ú¤w¬O¸Ñª¼«áªº¤F¡A¼Æ¾Ú¬Ý¦ü¤£¿ù¡A¦ý¥«³õ©l²×µLªk¤ÏÀ³¡A¦bªÃ«ù¥«³õ¬O¹ïªº±¡§Î¤U¡A¬Ý¨ÓÀ³¸Ó¬O¦³¤°»òt±¸ê°T¬O¤@¯ë¤HµLªkª`·N¨ìªº¡A¤£µM¥«³õ¤W³o»ò¦h±M·~§ë¸ê¤H«ç»ò·|¿ù¹LASLN ¡AªÑ»ù§C°g¤]¤£¬O¤@¤G¤Ñ¤F¡A¦Ü©óÀ£§C»ù®æ¦Y³fªº»¡ªk¡A°ò¥»¤W§¹¥þ¬Ý¤£¨ìÃÒ¾Ú¡A¨ì²{¦b³£ÁÙ¨S¦³«ùªÑ¶W¹L10%ªºªÑªF¥X²{¡A»ù®æ¤£¨ì0.5Ãø¹DÁÙÀ£ªº¤£°÷§C¡H 3.²z½×¤W²bȧﵽp¹ºÀ³¸Ó¬On¥i¦æ©Ê«Ü°ª¤~·|³QNasdaq±µ¨ü¡A¦ý¥H¥Ø«eª¬ªp¬Ý¤£¨ìASLN¨ã¦³¥ô¦óÄw¸ê¯à¤O¡A¦pªG¯uªº¯à©µ´Á¡A¥NªíASLNµ¹¤FNasdaq¥i¦æ©Ê«Ü°ªªºp¹º¡AÁ`¤§0603¨M©w¤FASLNªº¥Í¦º¡A¿N¤F³o»ò¦h¿ú´«¨Óe©µ´Ý³Ý¡A¥O¤H¤£³Ó®D¼N..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/4/23 ¤W¤È 10:23:29
²Ä 6622 ½g¦^À³
|
¦p©ú¤Ñ¤j©Ò»¡¡A³o¯uªº¬O³ÌµL¨}¾Þ§@ªü! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2024/4/23 ¤W¤È 09:50:08
²Ä 6621 ½g¦^À³
|
¬Ý°_¨ÓÁÙ¨S¸Ñª¼´N¥²¶·¤U¥«¡A°£«DÄ~Äò¤À©îªÑ²¼¡A¦A¨ÓÓ6¦X1¡AªÑ»ù¤S·|¤W¤É¨ì2¶ô¦h¡AÄ~Äò¼µ¤U¥h¡AµM«á¦A¨ÓÓ¼W¸ê¼W¥[ªÑ¥»¡A¤S¥i¥HÄFÓ¤@¦~Åo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/22 ¤U¤È 10:07:39
²Ä 6620 ½g¦^À³
|
ªGµM¤S¤½§i·s¼Æ¾Ú¡A¤ñ¤T¤ë¤½§iªº§ó¸Ô²Ó ¦]¬°¤H¼Æ¤Ö¼vÅTpÈ¡A³oÓµL¶Ë¤j¶®¡A ±M®a¬Ý¤F¤ß¤¤¦Û¦³©w¨£¡A¤j®a¥i¥H¤ñ¹ï£¸¤U¡A ¤µ¤Ñ¤½§i¼Æ¾ÚĶ¤å¦p¤U¡A¦³¿ù¦Û¦æ×¥¿¡C
ªº²×ÂI¡^¡C 66.7% (10/15) ªºeblasakimabªvÀø±wªÌªº vIGA µû¤À¬° 0 ©Î 1¡A¦Ó¦w¼¢¾¯²Õ¬° 14.3% (1/7) (p=0.0750)¡C ±µ¨üeblasakimabªvÀøªº±wªÌ®pÈ·kÄo¼Æ¦rµû¦ô¶qªí (PP-NRS) µû¤À¥§¡°§C 58.9% ¡A¦Ó¦w¼¢¾¯²Õ«h°§C 12.9% (p=0.0015)¡C°ò½uµû¤À¦Ü¤Ö 4 ªºeblasakimabªvÀø±wªÌ¤¤¦³ 53.8% (7/13) ªºPP-NRS µû¤À°§C 4 ¤À¡A¦Ó¦w¼¢¾¯²Õ¬° 14.3% (1/7) (p=0.2460)¡C ¦b¥ý«e¹ïdupilumab¤ÏÀ³¤£¨¬ªº 6 ¦W±µ¨üeblasakimabªvÀøªº±wªÌ¤¤¡A66.7% (4/6) ¹F¨ì EASI-90¡A66.7% (4/6) ¹F¨ì vIGA µû¤À 0 ©Î 1¡C
ªvÀø@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C¬¡©Ê²Õ©Î¦w¼¢¾¯²Õ¤¤¨S¦³µ²½¤ª¢©Îµù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C
°ò½u EASI µû¤À¬° 18 ©Î¥H¤Wªº¨È²Õ¸ê®ÆºKn
¦p¦P¥ý«e©Ò«Å¥¬ªº¡ATREK-DX ©Û¶Ò¼Ð·Ç©ó 2023 ¦~ 10 ¤ë¦¬ºò¡A¶È©Û¶Ò°ò½u EASI µû¤À¬° 18 ©Î¥H¤Wªº±wªÌ¡C³o¨Ç§óÄY®æªº¼Ð·Ç±N¦¨¬°¹wp¦b2024 ¦~©³¤½§Gªº³»½uŪ¼Æªº¤ÀªR°ò¦¡CÀø®Äµ²ªG¡G
±µ¨üeblasakimabªvÀøªº±wªÌªº EASI µû¤À¸û°ò½u¥§¡°§C 89.2% ¡A¦Ó¦w¼¢¾¯²Õ«h°§C 45.7% (p=0.0045)¡C 83.3% (10/12) ªºeblasakimabªvÀø±wªÌ¹F¨ì EASI-75¡A¦w¼¢¾¯²Õ¬° 0% (0/3) (p=0.0556)¡C 66.7% (8/12) ªºeblasakimabªvÀø±wªÌ¹F¨ì EASI-90¡A¦w¼¢¾¯²Õ¬° 0% (0/3) (p=0.1667)¡C 25% (3/12) ªºeblasakimabªvÀø±wªÌ¹F¨ì EASI-100¡A¦Ó¦w¼¢¾¯²Õ¬° 0% (0/3)¡]EASI-100 ¤£¬O¹w¥ý«ü©wªº²×ÂI¡^¡C 75.0% (9/12) ªºeblasakimabªvÀø±wªÌªº vIGA µû¤À¹F¨ì 0 ©Î 1¡A¦Ó¦w¼¢¾¯²Õ¬° 0% (0/3) (p=0.1111)¡C ±µ¨üeblasakimabªvÀøªº±wªÌPP-NRS µû¤À¥§¡°§C 61.2% ¡A¦Ó¦w¼¢¾¯²Õ«h¼W¥[ 1.5% (p=0.0004)¡C°ò½uµû¤À¦Ü¤Ö¬° 4 ªºeblasakimabªvÀø±wªÌ¤¤¦³ 60% (6/10) ªºPP-NRS µû¤À°§C¤F 4 ¤À¡A¦Ó¦w¼¢¾¯²Õªº¤ñ¨Ò¬° 0% (0/3) (p=0.2000)¡C ¤¤´Á¼Æ¾Ú±N´£¥æµ¹§Y±N¥l¶}ªº¬ì¾Ç·|ij¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/22 ¤U¤È 08:44:17
²Ä 6619 ½g¦^À³
|
ªoºj¤jªº¾á¼~¬O¦X²zªº¡A¤½¥q¯Ê¸êª÷ªº±¡ªp¤U¡A ±ÂÅv©Î¨ÖÁʽͧP¤£¯à¤Ó©T°õ¤v¨£¡AÁöµM¦³¥|¶g£¸°w¼ç¤O¡AÁö¦³»PDupilumab£¸¨M°ª¤UªººA¶Õ¡A ¦³¸êª÷¤~¯à¦s¬¡¡A¨ú±Ë¶¡»Ý¦Ò¼{§é°J¤è®×¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/22 ¤U¤È 07:49:06
²Ä 6618 ½g¦^À³
|
1¥»¤½¥q¦³¦Û¸Ó¨ç¥ó¤§¤é°_ 45 Ó¤é¾ä¤é¤º©Îª½¦Ü 2024 ¦~ 6 ¤ë 3 ¤éªº´Á¡A´£¥æ«·s¿í¦uªÑªFÅv¯qn¨Dªºp¹º¡C¦pªG¦¹Ãþp¹º³Q´£¥æ¨Ã±µ¨ü¡A¯Ç´µ¹F§J¥i¯à·|µ¹¤©¤½¥q¦Û¸Ó¨çµo¥X¤§¤é°_³Ì¦h 180 Ó¤é¾ä¤éªº©µ´Á¡A¥H«K¤½¥q«·s¿í¦u³W©w(¤]´N¬OÁÙ¦³180´Á¤Ñ¼e¡A¤j¬ù¦b10¤ë14¤é¥ª¥k)
2.2024 ¦~ 3 ¤ë¤w¤½§G¤FTREK-DX ¬ã¨sªºªì¨Bª¼¼Æ¾Ú¡C¦b¹ïTREK-DX ¬ã¨s¤¤±µ¨üªvÀøªº22 ¦W±wªÌªº¼Æ¾Ú¶i¦æ¼f¬d«á¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22) ªº±wªÌªºEASI µû¤À¦Ü¤Ö°§C¤F90%¡C¦b¥ý«e¹ïdupilumab¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ(56%) ¹F¨ìEASI-90¡A5 ¦W±wªÌ(56%) vIGA µû¤À¬°0 ©Î1¡CÂù¦b¦³¸g¾úªº AD ±wªÌ¸sÅédupilumab¡C¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo§G
3.¤½§i22¤H¦û¤ñ¬ù¦Ê¤À¤§30,³o»ò«æ©ó¤½§i¼Æ¾Ú¡A»¡¤£©w6¤ë¦A¤½§i45¤H¼Æ¾Ú(¦û¤ñ¦Ê¤À¤§60¡^¡A9¤ë¦A¤½§i60¤H¼Æ¾Ú¡]¦û¤ñ¦Ê¤À¤§80¡^ ¥H¤W¦sÄݲq´ú¡A¤j®a·Q·Q´£¨Ñª`·N¨ì¨ÖÁʪ̦ʤÀ¤§60¦Ü 80ªº¼Æ¾Ú¡A¤w¸g¦³¥i«H«×¡AÂù¤è¥i¥H¨Ì¨ÖÁÊ ºD¨Ò´£¨ÑÂùűø¥ó»P¼Æ¾Ú¡A¤££¸©wµ¥¨ì¦¬§¹75¤H ¤~½Í¨ÖÁʮסC
4¤¤ë¤¤»Ýª`·N¦³¨S¦³§ó·s¦¬®×²{ªp¡A¦³§ó·s ©Î¼W¥[¼Ú¬w¦¬®×¦aÂI¡A³o¬O¦n²{¶H
¥H¤W¤À¨É ¦sÄÝÓ¤H¬ã§P¡A¶È¨Ñ参¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/20 ¤W¤È 11:47:29
²Ä 6617 ½g¦^À³
|
ASLN¬Q¤Ñ¤S¤½§i¤F¦¬¨ìNASDAQªº¤U¥«³qª¾¡A³o¦¸¬O2023¦~©³²bȧC©óUSD250¸U¡An¦b6/3«e´£¥æ¦X³WªºªÑªFÅv¯q´£¤Ép¹º¡A¬Ý¤F¤@¤U2023¦~©³ªÑªFÅv¯q¬OUSD-1330¸U¡Aµ¥©óªÑªFªº¿ú³£¤w¸g¿N¥ú¤F¡A¤â¤W²{ª÷³£¬OɨӪº¡A¥H¥Ø«e¨Ó¬Ý¥ú¬O2023¦~©³ªº¼Æ¦rn¹F¼Ð´NnÄw¥XUSD1580¸U¡A¦Ó¥B±µ¤U¨ÓÁÙ¦b«ùÄò¿N¿ú¡A2024Q1°²³]¤]¬Oªá¶OUSD2000¸U¡A¨º´NnÄw¥XUSD3580¸U¡A¦ýnÅýNASDAQ±µ¨üªºp¹º¡A«ç»ò¥i¯à¥un´ê¨ì2024Q1ªÑªFÅv¯q¹F¼Ð´N¦n¡A¦ý¥HASLN¥Ø«eªºÄw¸ê¯à¤O°ò¥»¤WÄw¤£¥X¿ú¤F¡A©Ò¥H°ò¥»¤W´N¥u¦³³Q¨ÖÁʩάO®³¨ì¤jµ§±ÂÅvª÷¤~¥i¥H¸Ñ¨M¡A¨S·Q¨ìASLNªº©R¹B·|´£«e¶}¼ú¡A³strek-dx¸òfast-aaªºµ²ªG¥X¨Ó³£¼µ¤£¨ì......
**¥h¦~ASLNªº°]³ø¤½¥¬¨Æ¥ó¬O¤G¤ë©³¡A³o¦¸©ì¨ì²{¦b¤~¤½§G¤j·§²v´N¬O·Q©µ«á¤U¥«ªº®É¶¡§a¡A¬Ý¤F¤@¤U°]³ø¡A²ÖpÁ«·l¤w¸g¨ì¤FUSD3.2»õ¡A¤w¸g¿N¤F³o»ò¦h¿ú¡A¦¨ªG¤~³o¼Ë¡A¯u¬OªA¤Fªü«i¡A±Mªø¬O¨ÖÁʪº½Í§P¤j®v¡A³oºÙ¸¹«D§A²öÄݤF |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/18 ¤U¤È 02:05:15
²Ä 6616 ½g¦^À³
|
ADS¾ú¥v³Ì°ª52.195´N¬OÁÙì´î¸êªºµ²ªG¤F¡A´î¸ê«e³Ì°ªÀ³¸Ó¬O10¶ô¦h¡A©Ò¥H¥Î´î¸ê«á¨Ó¬Ý¼Ð·Ç¤ñ¸û¤@P¡A´N¬O¶^¤F99%¨S¿ù~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/4/18 ¤U¤È 01:55:22
²Ä 6615 ½g¦^À³
|
¨È«Í±d³oÄêªÑ±q¥¼¹F¨ì52¤¸¡A
¨º¬O¦]¬°³sÄò´î¸ê³y¦¨ªº |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/18 ¤W¤È 11:31:24
²Ä 6614 ½g¦^À³
|
¼ÖÆ[ªº¤H¥i¥HÄ~Äò¼ÖÆ[¡A¦ý²{¹ê´N¬O¦p¦¹¡A»¡¤@¤U¨Æ¹êÁÙn³Q»¡¬O§O¦³¥Î¤ß¬Ý°IªÑ»ù¡Aþ»Ýn¬Ý°I¡A¬Ý¤£¨ì±ÂÅv©Î¨ÖÁʶi«×¡AÄ~Äò¿N¿ú¡AªÑ»ù´N¬Oª½±µ¤U¥h¤Fªü¡A¥h½½Â¤å¡A¨º¨Ç©úÅã¼ÖÆ[ªº¹w´ú¡A¦Ü¤µþÓ¦³¹w´ú¦¨¥\?
©t¨àÃĤj¤]¬O¦Ñ·à¤Í¤F¡A³o¤@¸ô¨«¨Ó·Q¥²ÂIºw¦b¤ßÀY¡A½Í§P¤j®v´N¬O¤@ª½·dÄê¦ÑªÑªFªºÅv¯qªü¡A¬Ý¬Ý·íªìªºì©lªÑªF¡A±q²H°¨¿ü¡BÀq§J¤l¤½¥qµ¥¡A¨ì«á¨Óªºtang¡A²{¦b³£¤£¦b¤F¡A¦p¦¹¦³«e´º¸ò·ÓÅUªÑªFªº¤½¥q·|³o¼Ë?±q¥xªÑ¤W¥«¨ì²{¦b°ò¥»¤WªÑ»ù´N¬O¤@¸ô±Y¶^¡AADS¾ú¥v³Ì°ª52.195¨ì²{¦b0.5¤£¨ì¡A¶^´T¶W¹L99%¡A¤j·§¬O¸}¥Ö±Ù¤F¡A¦pªG¬O±q¥xªÑÂà´«¹L¨Óªº¦Ñ·à¤Í¡A«áÄò¨S¥[½Xªº¸ÜÀ³¸ÓÁ«·l¤]³£¶W¹L9¦¨¡AªÑ»ù½10¿³£ÁÙ¤£¤@©wÁÈ¿ú¡A¥u¯à«ü±æASLAN¦³©_ÂÝ¥X²{¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/4/17 ¤U¤È 04:01:19
²Ä 6613 ½g¦^À³
|
°ò©ó¥ý«e´X¦¸½Í§P¤j®vªº¦¨ªG¡A´X¥G¬O¥HÄ묹¦ÑªÑªFªºÅv¯q¦¬³õ¡A©Ò¥H¥u¯à¹³¨â©¤³Ìªñ¤õ¬õªº¹q¼v©P³B°£¤T®`¡A½Í§P¤j®v¥ý¤U¥xªº¸Ü¡Aªü·à·d¤£¦n´N·|¤j½¨¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/17 ¤W¤È 11:42:47
²Ä 6612 ½g¦^À³
|
ASLAN¤½§iªº³Ì·s¤½¥q¶i«×¡A°£¤FFarudodstat±q2024¦~¤¤¤S¨Ç·L©µ¿ð¨ì2024Q3¥~¡AÓ¤H»{¬°ÁÙ¦³¤GÓ«ÂInª`·N
1.Eblasakimab ¼Ú¬w¦¬®×¶}©l¤F¨S?clinical trail©|¥¼§ó·s¼Ú¬w¦¬®×¦aÂI¡A¤§«e¬O»¡¹wp2024Q2¶}©l¼Ú¬w¦¬®×¡A¦A¤£»°§Ö¶}©l¡ATREK-AD2024¦~©³¼Æ¾Ú¥Xªº¨Ó?
2.³o¬O§Ú»{¬°³Ì«nªº¤@ÂI¡AASLAN¥Ø«e¤½¥¬ªº¶i«×§ó·s¤w¸g¨S¦³´¦ÅS±b¤W²{ª÷¾lÃB¤Î¹wp²{ª÷¥i¨Ï¥Î¦Ü¦ó®É¡A¤§«e¬O¹wp¥i¥H¥Î¨ì2024¤U¥b¦~¡A¦ýºI¤î2023/12¤ë©³¡A±b¤W²{ª÷¥u³Ñ21.3M¡A¿N¿úªº³t«×¤ñ·Q¹³¤¤§Ö¡AÀ³¸ÓQ1²{ª÷´N¿N¥ú¤F¡A³o¤@¤è±Ë¬O¨S¬Ý¨ìASLAN°µ»¡©ú¡A¤£ºÞ¬O¥¼¨Ó¹wp¨p¶ÒÁÙ¬O¥t¦³³W¹º?
°ò©ó¥H¤W²{¹êªº¦Ò¶q¡AASLAN¯uªº¦³¦X§@¹ï¶H¥i¥H¶i¤J¤T´Á¡AÀ³¸ÓQ2´Nn·Ç³Æ¦X§@¶i¤J¤T´Á¤F¡A±ø¥ó§Y¨Ï¤£²z·Q¤]¥u¯à§]¤F¡A½Ö¥s½Í§P¤j®vª±¨ì¨S¿ú¨S©³®ð¤F©O?¤S©ÎªÌASLANÄ~Äò¦LªÑ²¼´«¶r²¼¡A¦ý¥H¥Ø«eªÑ»ù¨Ó¬Ý¡A¶Ò¸ê®Ä²v·¥¬°§C¸¨¡A¥u¯à»¡¹ï·à¤Í̪º¦n³B´N¬OASLAN¶Õ¥²Q2n¦³¤j°Ê§@¤F¡A¤£¥ÎWWµ¥ÔFAST-AA¸òTREK-DXªº¼Æ¾Ú¥X¨Ó¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/16 ¤U¤È 11:06:11
²Ä 6611 ½g¦^À³
|
¢±¢¯¢±¢²¦~¡@²Ä¥|©u©M³ÌªñªºÁ{§É¶i®i«ÂI¡@¡@¡]FAST-AA ¬ã¨s²{¤w©Û¶Ò¤Fªñ 75% ¡^
2023 ¦~ 10 ¤ëeblasakimabªvÀø¤¤««× AD ªº2b ´Á TREK-AD ¬ã¨sªº·s¼Æ¾Ú¦b²Ä 32 ©¡ ¼Ú¬w¥Ö½§¯f¾Ç©M©Ê¯f¾Ç¦~·|¤Wªº³Ì·s¤fÀY³ø§i¤¤´£¥X¡C
2023 ¦~ 10 ¤ë¡AÁ|¿ì¤F¤@³õÃö©ó AD Á{§É¸ÕÅç©MªvÀø®æ§½ÅܤƪºÃöÁä·N¨£»â³S (KOL) ¬¡°Ê¡C ASLAN »P»â¥ýªºÁ{§É¬ã¨s²Õ´©M KOL Jonathan Silverberg¡]³ìªvµØ²±¹y¤j¾ÇÂå¾Ç»P°·±d ¬ì¾Ç¾Ç°|¡^©M April W. Armstrong¡]¥[¦{¤j¾Ç¬¥§üÁF¤À®Õ¡^Âå¾Ç³Õ¤h MPH¡]Âå¾Ç³Õ¤h MPH¡^ ¦@¦PÁ|¿ì¤F§ë¸êªÌ¬¡°Ê¡C¦b¦¹¦¸¬¡°Ê¤¤®i¥Üªº TREK-AD ¬ã¨s¤¤¹ï§óÄY«±wªÌ¡]°ò½u EASI 18 ©Î§ó°ª¡^ ªº·s¤ÀªR¤¤¡A¨C 4 ¶g±µ¨ü 600 ²@§J¨Ì¥¬©Ô§Æ³æ§ÜªvÀøªº±wªÌ¤¤¡A55.6% ªºEASIµû¤À¦Ü¤Ö°§C¤F75% ¡]EASI -75¡^¬Û¤ñ¤§¤U¡A¦w¼¢¾¯²Õªº±wªÌ¬°15.4%¡A¦bIGA 0/1 ¦w¼¢¾¯²Õªº±wªÌ¬°8.0%¡A ¹êÅç²Õ30.6% ªº±wªÌÀò±o¤F0 ©Î1 ¤À¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^
2023 ¦~ 11 ¤ë¡Aº¦¸¦beblasakimabªº AD ¥H¥~¾AÀ³¯g¤¤´£¨Ñ¼Æ¾Ú¡C¦b¥Ö½§¬ìÃĪ«¶}µo°ª®p·|¤W¡A ASLAN³z¹LºC©Êªý¶ë©ÊªÍ¯f (COPD) ªº¤HÃþÂà¤Æ¼Ò«¬®i¥Ü¤Feblasakimab¦b AD ¥H¥~ªº¾AÀ³¯g¤¤ªº ¼ç¦b¥Î³~¡C¼Æ¾ÚÅã¥Ü¡Aeblasakimab¥i¦³®Ä°§C IL-4 ©M IL-13 ÅX°Êªº®ð¹D°ª¤ÏÀ³©Ê¡C
2023 ¦~ 12 ¤ë¡A´¦ÅS¤F¥¿¦b¶i¦æªºFarudodstatªvÀø´³¨r (AA)ªº 2a ´Á FAST-AA ¬ã¨sªºª¼ªk ¦w¥þ©Ê¼Æ¾Ú¡C¼Æ¾ÚÅã¥Ü¡A¨´¤µ¬°¤î¡A¤J²Õ±wªÌ¨S¦³¨xŦ©Î¨ä¥L¥Dn¦w¥þ°ÝÃD¡A³o¤ä«ù¤FFarudodstat »P²Ä¤@¥N§å㪺¤G²B¨Å²M»Ä²æ²B酶 (DHODH) §í¨î¾¯¬Û¤ñ¡A¦w¥þ©Ê¦³©Ò§ïµ½¡CFarudodstat¬O¤@ºØ °ª¿ï¾Ü©Ê¤fªA DHODH §í¨î¾¯¡A¦³¼ç¤O¦¨¬° AA ªº¤@¬yªvÀøÃĪ«¡C FAST-AA ¬ã¨s²{¤w©Û¶Ò¤Fªñ 75% ªº±wªÌ¡A¸Ó¬ã¨sªº¥Dn¤¤´Á¼Æ¾Ú¹wp±N©ó 2024 ¦~²Ä¤T©u´£¨Ñ¡C
2024¦~2¤ë¡A¨ú±o¼Ú¬w±M§Q§½¡]EPO¡^Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¦³§Q·N¨£¡C ¼Ú¬w±M§Q§½¾á¥ôFarudodstat¦h´¹«¬±M§Q¥Ó½Ðªº°ê»Ú¼f¬dû¡A¦pªG¦b°ê®a¶¥¬qÀò±o§åã¡A ±N§âFarudodstatªº¦³®Ä±M§Q«OÅ@©µªø¦Ü¦Ü¤Ö 2043 ¦~¡C
2024 ¦~ 3 ¤ë¡A«Å¥¬¤Feblasakimab»Pdupilumab¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¶i¦æªºÀY¹ïÀY¬ã¨sªº¿n·¥Âà¤Æ¼Æ¾Ú¡C ¦b¬ã¨s¤¤¡A¦b¬Û¦P¿@«×¤U¡A e blasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è±¤ñdupilumabªí²{§ó¦n¡A
¬°eblasakimab§@¬° COPD ¥Íª«Àøªkªº¼ç¤O´£¨Ñ¤F¶i¤@¨B¤ä«ù¡C³o¨Ç¼Æ¾Ú¤w´£¥æµ¹§Y±N¥l¶}ªº¬ì¾Ç·|ij¡C 2024 ¦~ 3 ¤ë¡A¤½§G¤FTREK-DX ¬ã¨sªºªì¨Bª¼¼Æ¾Ú¡C¦b¹ïTREK-DX ¬ã¨s¤¤±µ¨üªvÀøªº22 ¦W±wªÌªº¼Æ¾Ú¶i¦æ¼f¬d«á¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22) ªº±wªÌªºEASI µû¤À¦Ü¤Ö°§C¤F90%¡C¦b¥ý«e¹ïdupilumab¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ(56%) ¹F¨ìEASI-90¡A5 ¦W±wªÌ(56%) vIGA µû¤À¬°0 ©Î1¡CÂù¦b¦³¸g¾úªº AD ±wªÌ¸sÅédupilumab¡C¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo§G
¹wp§Y±N¨ì¨Óªº¨½µ{¸O ( °Ñ¦Ò2024 04 12 ¤½¥q°T®§ ¤½¥qºô¶¥þ±§ó·s )
¦b§Y±N©ó 2024 ¦~²Ä 2 ©u¥l¶}ªº¬ì¾Ç¤j·|¤W®i¥Ü¤Feblasakimab»Pdupilumab¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤ªº ÀY¹ïÀY¬ã¨sªº¿n·¥Âà¤Æ¼Æ¾Ú
AA ªºfarudodstat 2a ´Á¬ã¨sªº¥Dn¤¤´Á¼Æ¾Ú¹wp±N©ó 2024 ¦~²Ä¤T©uµo§G (Ó¤Hµû½×¡G²Ä¤T©u 7 8 9¤ë §é¤¤ ¥H 8¤ëµo§G¾÷·|³Ì¤j)
eblasakimabªº TREK-DX ¸ÕÅ窺¥Dn¼Æ¾Ú¹wp±N©ó 2024 ¦~©³µo¥¬ ( Ó¤Hµû½×¡G¤w¸g¤½§G 22¤H/75¤H ¼Æ¾Ú ³£¥l¦¬¢Ó¢Ï¢á¢×18¤À¥H¤W ¤T¤À¤§¤G¦b¹êÅç²Õ ¼Æ¾ÚÀ³¦b¹w´Á¤¤ )
¿ï¾Ü¶}µo¦X§@¹Ù¦ñ¥H±Neblasakimab±À¶i AD ©M¨ä¥L¾AÀ³¯gªº 3 ´Á Á{§É ( Ó¤Hµû½×¡G§¹¦¨¤G´ÁªºÃĪ« ¤T´ÁÁ{§É¥i¥H©Ý®i¨ä¥L¾AÀ³¯gªº3´ÁÁ{§É ¡@´N¦n¹³Dupilumab °£¤F¶}µoAD¡@¥~¤]©Ý®i¨ä¥L¾AÀ³¯g)
¥H¤WÓ¤Hµû½×¡@¶È¨Ñ°Ñ¦Ò¡@¡@§¹¾ã¸ê°T½Ð°Ñ¦ÒApril 12, 2024 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/4/12 ¤U¤È 06:38:24
²Ä 6610 ½g¦^À³
|
°]³ø¥XÄl¡A¬Ý¨Ó¤T¤ë¯uªº¬O¿ú§Ö¿N¥ú¤F¡A¥u¯à§C»ù¦LªÑ²¼´«¶r²¼¡AºI¤î2023/12¤ë©³¡A±b¤W²{ª÷¥u³Ñ21.3M¡A¹ï¤ñ2023¦~Q4Á`¦@¿N¤F20.4M¡A±b¤W²{ª÷®Ú¥»¼µ¤£¨ìQ2¡A§Y¨ÏQ1¦LªÑ²¼´«¦^5M¡A¬Ý°_¨ÓÁÙ¬OªM¤ô¨®Á~¡A©Ò¥H»¡¹Ln¹M¤F¡A®É¶¡©ì¶V¤[¶V¤£§Q´N¬O³o¼Ë¡AÁ`¤§n¹À³Ìªñ¯uªº¦³¦X§@¹Ù¦ñ´Nn»°§ÖºV©w¤F¡A¤£µM´N¬OÄ~Äò¦LªÑ²¼¨Ó¼µ¡A¦ý§A¦U¦ì·Q¤@¤U¡AªÑ¥»¿±µÈ¨º»ò¦h¤~®³¨ì5M¡An¦L¨ì°÷¼µ¨ì¦~©³¡AªÑ¥»·|¿±µÈ¨ì¦h¤j§Ú¬O¤£´±·Q¹³°Õ¡AµM«á½Í¨ì²{ª÷¿N¥ú¡AAD¤T´ÁÁÙ»»»»µL´Á¡A¯uªº¬O½Í§P¤j®v¡I¡H«ô°Ucarl firth§Ö¨Ó¥´§ÚÁy¡A¦V·à¤ÍÌÃÒ©ú¦Û¤v¹ê¤O§a¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/4/5 ¤U¤È 10:54:31
²Ä 6609 ½g¦^À³
|
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
A TRED-DX ¥l¶Ò75¤H (¹êÅç²Õ50¤H 400mg QW ¹ï·Ó²Õ25¤H)
B ¯Ç¤J¼Ð·Ç¡G
≥18·³ªº¨k©Ê©Î¤k©Ê°Ñ»PªÌ Ä@·N¨Ã¥B¯à°÷¿í¦uªù¶E©M¬ã¨s¬ÛÃöµ{§Ç ¿zÀË«eºC©Ê AD ¤w¦s¦b¦Ü¤Ö 1 ¦~ °ò½u®É vIGA µû¤À≥3 °ò½u®É AD ¨ü²Ö BSA ≥10% ¿zÀË©M°ò½u®É EASI ≥18 ¹ï§½³¡¥Ö½èÃþ©T¾J (TCS) ©Î§½³¡¶t½Õ¯«¸gÁC»Ä酶§í¨î¾¯ (TCI) éw¤è®×ªvÀø AD ¤ÏÀ³¤£¨¬¡B¤£@¨ü©Î¸T§Òªº¯f¥v ©Ò¦³°Ñ»PªÌ¤§«e¥²¶·±µ¨ü¹L dupilumab ªvÀø¡A¥B²Å¦X¥H¤U±ø¥ó¤§¤@¡G
¦]µL¤ÏÀ³¡B³¡¤À¤ÏÀ³¡BÀø®Ä³à¥¢¦Ó°±¤î dupilumab ªvÀøªº°Ñ»PªÌ¥²¶·¥ý«e±µ¨ü¹L dupilumab ªvÀø¦Ü¤Ö 16 ¶g¡F ¥Ñ©ó¹ïÃĪ«¤£@¨ü©Î¤£¨}¨Æ¥ó (AE) ¦Ó°±¤î dupilumab ªvÀøªº°Ñ»PªÌ¥i¥H¶i¤J¬ã¨s¡AµL»Ý¨Æ¥ý±µ¨ü dupilumab ªvÀøªº®É¶¡ªø«×¡F ¦]¶O¥Î©ÎµLªkÀò±o dupilumab ©Î¥ô¦ó¨ä¥Lì¦]¦Ó°±¤î dupilumab ªvÀøªº°Ñ»PªÌ¥i¥H¶i¤J¬ã¨s¡AµL»Ý¨Æ¥ý±µ¨ü dupilumab ªvÀøªº®É¶¡ªø«×¡F
C ¦h¤¤¤ß¡BÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¥¦æÁuÁ{§É¬ã¨s¡A¦®¦bµû¦ô eblasakimab ¹ï¥ý«e±µ¨ü dupilumab ªvÀøªº¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢ (AD) °Ñ»PªÌªºÀø®Ä©M¦w¥þ©Ê¡C¬ã¨s¥]¬A 16 ¶µ¬ã¨s¶gªvÀø´Á©Mª½¦Ü²Ä24 ¶gªº8 ¶g°lÂÜ´Á¡C²Å¦X±ø¥óªº°Ñ»PªÌ±N³QÀH¾÷¤À°t¨ì2ÓªvÀø²Õ¤§¤@
2024¦~3¤ë ²³ø P25 2024 ¦~ 2¤ë¶i¦æ ªºªì¨Bª¼ªk¸ê®Æ¼f¬d¡A¥]¬A¨´¤µ¬°¤î¤J²Õªº©Ò¦³ 22 ¦W±wªÌ¡G17 ¦W±wªÌ§¹¦¨¤F 16 ¶gªºªvÀø´Á¡A 5 ¦W±wªÌ¦b¦¹¤§«e°±¤îªvÀø 45% ªº±wªÌªº EASI µû¤À (EASI-90) °§C¤F¦Ü¤Ö 90%¡A50% ªº±wªÌ¹F¨ì¤F vIGA µû¤À 16 ¶g«á¬° 0 ©Î 1¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^
¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90 ¥B 5 ¦ì±wªÌ (56%) vIGA µû¤À¬° 0 ©Î 1 ªvÀø@¨ü©Ê¨}¦n¡A¥¼µo²{·sªº¦w¥þ°T¸¹¡C ¨S¦³µ²½¤ª¢©Îµù®gªº³ø§i²{³õ¤ÏÀ³
Ó¤Hµû¦ô: 5¤ëÓ¤¤¥ª¥k»Ý¦¬§¹³Ì«á¤@¦W¨ü¸Õ ( ªvÀø»P«áÄò°lÂܦ@24¶g (6Ó¤ë) ¦p¦¹¤~¯à¦b¦~©³¤½§iTRED-DX ¼Æ¾Ú
¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº 9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90 ¥B 5 ¦ì±wªÌ (56%) vIGA µû¤À¬° 0 ©Î 1 ( ¤½§i³o¤@¬q «Ü@¤H´M¨ý, ·Pı¤½¥q«H¤ß¤Q¨¬ TREK-DX ¬O TREK-AD ªº©µªøÁÉ)
TREK-DX ¸ÕÅç 2024 ¦~©³¤½§i Topline readout • ¿ï¾Ü¦X§@¹Ù¦ñ±N eblasakimab ±À¶i¨ìÁ{§É3 ´Á • 2024¦~¤¤´Á ¤½§iFarudodstat 2a ¶¥¬q ´Á ¤¤ Topline data • TREK-AD ¬ã¨sªº¶i¤@¨B¼Æ¾Ú±N¦b«n·|ij¤Wµoªí¨Ã®i¥Ü (eblasakimab ©M farudodstat)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/26 ¤U¤È 05:25:17
²Ä 6608 ½g¦^À³
|
®Ú¾ÚSEC¸ê®Æ¡A¥Ø«e¤jªÑªF¤S¦h¥Ó³ø¤FINTRACOSTAL LLC(4.4%)¸òLIND GLOBAL FUND(5.7%)¡A³£¬O³o¤@¦¸ªº¨p¶Ò¹ï¶H¡AªÑ¥»¿±µÈ«á¥Ø«e¤w¸g¨S¦³«ùªÑ¶W¹L10%ªºªÑªF¤F¡A¥hª¦ª¦Â¤å¡A±q2023¦~7¤ë¸Ñª¼ªÑ»ù±Y¶^¡A¦³¨Ç¤@ª½¥D±i¥D¤O¦b¦Y³f¡A±q4.X±Y¨ì0.4¨ì²{¦b0.6X¡A®É¶¡¤w¸g¹L¤F§Ö9Ó¤ë¡A¦³½Ö§ä¨ì¦Y³fªº¥D¤O¤F¶Ü¡A¤p§Ì¸ê½è¾q¶w§ä¤£¤Ó¥X¨Ó³â¡AµM«á¹L¤F9Ó¤ëÁÙ¨S§ä¨ì¤H¤@°_±À¶i¤T´Á¡A§Ú¬Ý¤]¬O¤¿¦h¦N¤Ö.....
**°¸º¸À°¦Ñ·à¤Í§ó·s¤@¤USECªº¸ê®Æ¡A¤£µMSEC³o»ò¤Î®É¸ò·Ç½T³£¨S¤Hn¬Ý¡A³£¶]¥h¬Ý¤@¨Çºô¯¸µM«á¸£¸É¤@°ï¤p¼@³õXD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/3/18 ¤U¤È 10:43:25
²Ä 6607 ½g¦^À³
|
§CÀɼɺ¦¼É¶^ ³o¬O¤£¬O¥s¾_Ü¥ÏÃâªü...... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/18 ¤U¤È 10:42:40
²Ä 6606 ½g¦^À³
|
§ó¥¿»P¸É¥R
Duplimab ¨âÓ¤T´ÁÁ{§É¡A¹êÅç²Õ»P¹ï·Ó²Õ¤H¼Æ¬ù²¤¬Û¦P¡A
TRED-DX¹êÅç²Õ»P¹ï·Ó²Õ¤H¼Æ¤ñ昰50¤H/25¤H¡A¦¬®×¹ï¶HEASI ¦Ü¤Ö18¤À¥H¤W¡A¥ÎÃÄ16¶g¡A³o22¤Hblinded data ·íµM¥ÎÃIJթâ¨ì¤H¼Æ·|¤ñ¹ï·Ó²Õ¦h¡C
¥t¥~¤½¥q°T®§¤¤¦³´£¨ì£¸¤p¬q@¤H´M¨ýªº¸Ü¡Aȱoª`·N ³o9¤H·|¤£·|´N¬O¹êÅç²Õ
9¦W±wªÌ¤¤¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90¡A5 ¦W±wªÌ (56%) ¹F¨ì vIGA µû¤À¬° 0 ©Î 1¡C¨´¤µ¬°¤î¡AªvÀøªº@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹,¨S¦³µo²{µ²½¤ª¢¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/18 ¤U¤È 09:01:46
²Ä 6605 ½g¦^À³
|
eblasakimab ¥¼¨Ó¦³¾÷·|»PDupilumab¶i¤JÄvª§¡A¹ï¤âªº¼Æ¾ÚÅܦ¨«Ü«nªº«ü¼Ð¡AÃĪ«ªº¬ãµo¨S¦³§¹¬üªº³Ì¦n¡A¥u¦³¤£Â_³Ð·sªº§ó¦n
Dupilumab SOLO1¬ã¨s ¹F¨ì IGA score 0 or 1 ¹ï·Ó²Õ¤H¼Æ224¤H¤¤¦³23¤H(10%)¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@85¤H( 38¢H)¹F¼Ð
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@83¤H( 37¢H)¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-75 ¦@115¤H( 51¢H)¹F¼Ð
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìI EASI-75 ¦@117¤H( 52¢H)¹F¼Ð
EASI-90 ¹ï·Ó²Õ224¤H¤¤¦³17¤H 8¢H¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-90 ¦@80¤H( 36¢H)¹F¼Ð
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìEASI-90 ¦@74¤H( 33¢H)¹F¼Ð
Dupilumab SOLO2¬ã¨s
¹F¨ì IGA score 0 or 1 ¹ï·Ó²Õ¤H¼Æ236¤H¤¤¦³20¤H(8%)¹F¼Ð
¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìIGA score 0 or 1 ¦@84¤H( 36¢H) ¹F¼Ð¡C
¹êÅç²Õ223¤H¨C¶g¤@°w¹F¨ìIGA score or 1 ¦@87¤H( 36¢H)¹F¼Ð
¹êÅç²Õ236¤H¨â¶g¤@°w¹F¨ìEASI-75 ¦@103¤H( 44¢H)
¹êÅç²Õ224¤H¨C¶g¤@°w¹F¨ìEASI-75 ¦@115¤H( 48¢H)¹F¼Ð
EASI-90 ¹ï·Ó²Õ236¤H¤¤¦³17¤H 8¢H¹F¼Ð ¹êÅç²Õ224¤H¨â¶g¤@°w¹F¨ìEASI-90 ¦@70¤H( 30¢H)¹F¼Ð
¹êÅç²Õ223¤H¨C¶g¤@°w¹F¨ìEASI-90 ¦@73¤H( 31¢H)¹F¼Ð
¥H¤U昰Dupilumabµoªí¦b·s^®æÄõÂå¾Ç´Á¥Z¨âÓ¤T´ÁÁ{§Éªº¹Ïªí¼Æ¾Ú
½Æ»s«á·j´M phase 3 trials of dupilumab versus placebo in atopic dermatitis nejm ©¹¤U§ä¨ì Results «ö¤U¥h¥i¥H§ä¨ì¹Ïªí1»P¹Ïªí2
¬ÛÃö°ò¥»¸ê®Æ»PÁ{§É¼Æ¾Ú¡AÀ³¦³ºÉ¦³¡C
¥»¦¸22¤H¥¼¸Ñª¼ªì¨B¤ÀªR¡A45%¹F¨ìEASI-90 10/22¡A¦Ê¤À¤§50¹F¨ìIGA score o/1 11/22¡A¨ä¤¤·|¦³¦h¤Ö¤H¨Ó¦Û¹ï·Ó²Õ¡A¥i¥H参¦ÒDupilumab SOLO1,SOLO2 ¨âÓ¤T´ÁÁ{§É¤¤ ¹ï·Ó²Õ¦bEASI-90,IGA score o/1¦û¤ñ¡A¥i¬Ý¥Xªì¨BºÝÙ¡A ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¼Æ¾Ú¥H·s^®æÄõÂå¾Ç´Á¥Z¬°¥D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 11:07:31
²Ä 6604 ½g¦^À³
|
SOLO1¹F¨ì vIGA 0 or 1 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§10¡A¹êÅç²Õ¹F¨ìvIGA 0 or 1 ¬ù¦b¦Ê¤À¤§37~38 SOLO2¹F¨ìvIGA 0 or 1 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§8¡A¹êÅç²Õ¹F¨ìvIGA 0 or 1 ¬ù¦b¦Ê¤À¤§36
¥»¦¸¤½§iªº22¤Hªì¨B¥¼¸Ñª¼¼Æ¾Ú昰 ¦³¦Ê¤À¤§50ªº¤H¹F¨ìvIGA 0 or 1 ±q¹L¥hdupilumab¨âÓ¤T´ÁÁ{§É¼Æ¾Ú¨Ó¬Ý¡A³o11Ó¤H¹F¼Ð¤¤¦³¦h¤Ö¤H昰¹ï·Ó²Õ¦P¼ËÃø«×¬Û·í°ª 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 10:37:20
²Ä 6603 ½g¦^À³
|
1ªoºj¤j«e«h¤À¨É¬O¥¿½Tªº¡A§Ú¿ù§â±µ¨üªvÀø22¤H¥þ³¡·í¬°¹êÅç²Õ¡A³oÓ昰blinded data,¦~©³¤½§iªº¤~¬Ounblind data ¡A¤]´N¬O¸Ñª¼ªº¼Æ¾Ú¡C 2¤½¥q¤½¥qªº^¤å¥þ¤å In a preliminary review of blinded data from 22 patients treated to date, 45% (10/22) of patients saw at least a 90% reduction in their EASI score (EASI-90) and 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline unblinded data from the full dataset is expected at the end of 2024
3´N§Ú¦L¶H©Ò¤Î¡Adupilumab¨âÓ¤T´ÁÁ{§É SOLO1¹F¨ìEASI90 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§8¡A¹êÅç²Õ¹F¨ìEASI90 ¬ù¦b¦Ê¤À¤§33~36 SOLO2¹F¨ìEASI90 ¹ï·Ó²Õ¬ù¦b¦Ê¤À¤§7¡A¹êÅç²Õ¹F¨ìEASI90 ¬ù¦b¦Ê¤À¤§30~31 ³o¦¸¤½¥q¤½§iªº22¤H¥¼¸Ñª¼ªºªì¨B¼Æ¾Ú¡A¹ï·Ó²Õn¦³¦Ê¤À¤§45ªº¨ü¸Õ¹F¨ìEASI90Ãø«×¬Û·í°ª¡A ¤j®a´N@¤ßµ¥«Ý¡Aµ¥«Ý¼Æ¾Ú»¡¸Ü¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/17 ¤U¤È 07:43:36
²Ä 6602 ½g¦^À³
|
¥xÁÞ¤j³£»¡¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü¤F¡A§Ú´N¸É¥R¥H¤U´XÂI´N¦n¡G 1.¥»¦¸¨p¶Ò500¸UªÑ+»{ªÑÅvÃÒ500¸UªÑ¡A¨Ã¨S¦³³¬Âê´Á5¦~ªº°ÝÃD¡A»{ªÑÅvÃÒ5¦~¨ì´Á¬O«üµo¦æ«áÀH®É¥i¥H¥Î1¤¸ÁʶR¡A»{ªÑÅv5¦~«á¨ì´Á´N¥¢®Ä¤F¡A¨p¶Ò§¹ªÑ¥»¿±µÈ3¦¨¡A»{ªÑÅvÃÒ³£¦³¦æ¨Ï¡AªÑ¥»¿±µÈ6¦¨¡A¦pªG¨ÖÁÊ»ù®æ¤£ÅÜ¡AªÑ¥»¿±µÈ3~6¦¨µ¥©ó¨CªÑ»ù®æ¤Ö¤F25%~40%¡A§Ú¬O¤£»{¬°³o¥sªÑ¥»¼W¥[¤£¦h°Õ¡A°²³]10»õ¬ü¦¬ÁÊ¡AìªÑ¥»¤@ªÑ60¤¸¡A¿±µÈ«á·|¥u³Ñ24~45¤¸¡A³o¥u¬O²{¦³ªº¼Æ¾Ú³á¡AÁÙ¤£ºâ¤W¤§«á¦³¥i¯àÄ~Äò¼W¸ê... 2.³o¦¸TREK-DX¤½¥¬ªºªì´Á¼Æ¾Ú¬O¥¼¸Ñª¼¼Æ¾Ú¡A«üªº¬O³o22Ó§¹¥þ¤£ª¾¹D¹êÅç²Õ¸ò¹ï·Ó²Õªº¤À°t¡A©Ò¥H¥xÁÞ¤j§â³o22Ó³£ºâ¨ì¹êÅç²Õ¨ä¹ê¬O¿ù»~ªº¡A³o22ÓÀ³¸Ó¬O¹êÅç²Õ¹ï·Ó²Õ³£¦³¡An¸Ñª¼¤~·|ª¾¹D¦p¦ó¤À°t¡A©Ò¥HTREK-AD¤G´Á¸Ñª¼·|±Y·´¸òCNTB¤@¼Ë¡A¬Ý¨ìªì´Á¼Æ¾Ú³£Ä±±oÀø®Ä¶W¦n¡]¦]¬°³£¤ñ·Ó§ù¥²ª¢ªº¹ï·Ó²Õ¼Æ¾Ú¡^¡A«á¨Ó¸Ñª¼«á¤~µo²{ì¨Ó¹ï·Ó²Õ¦³§ïµ½ªº¤ñ¨Ò·¥°ª¡A¾ÉP¹êÅç²Õ¸ò¹ï·Ó²Õ®t¶Z¨S¦³©Ô¶}¡A©Î³\¦¬®×¼Ð·Çקï¥i¥H§ïµ½¡A¦ý§âªì´Á¼Æ¾Ú³£·í¦¨¹êÅç²Õ³o¼Ë·|¾ÉP»~§P¡A§O§Ñ¤FTREK-DX¤G´ÁªººGªp¡A¹ê»Úµ²ªGÁÙ¬O¥H¸Ñª¼¥X¨Ó¦A»¡§a... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 03:43:33
²Ä 6601 ½g¦^À³
|
¥t¥~½Í¨ì¤Ñ©R¤jªº±ÂÅvª÷±À¦ô¡A§Ú»{¬°¬O¦X²zªº±À¦ô¡A´«¦¨£¸¯ë§ë¸ê¤H¤]·|¥Î¤½¥q±ÂÅvµ¹¤é¥»ªºª÷ÃB°£¥H¤é¥»ÃÄ«~¥«³õ¥«¦û²v¡A·íµM³o¬O·§²¤¦ôºâ¡A¤½¥q¥Ø«eµ¦²¤¦A昰±À¥X´³¨rÃĪ«¡A³oÓ¤G´Á¬ã¨sFAST-AA ¤TӤ륪¥k´Nn¤½§i¼Æ¾Ú¡A¥H´£°ª¤½¥q»ùÈ¡A³o¤äªÑ²¼¤W¤W¤U¤U¡AÅý§ë¸ê¤H¤ß¦Ç·N§N¡A¥Ø«eªÑ»ù§¹¥þ¨S¦³¤ÏÀ³À³¦³ªº»ùÈ¡A¯u¥¿·N¹Ï¤£©ú¡H¥u¦³®É¶¡¤~¯àµ¹¥Xµª®×¡A昰n§â´²¤áÄw½X¥þ§l¨«À£§C¶i³f¡A¦A¤j´T©Ô¤É¡A¦A«Å§G¨Ö©Î±ÂÅvª÷¡A¦Y¹¡³Ü¨¬¡A¥u¦³¤½¥q¬£¡A¤jªÑªF¡A¤jªº§ë¸ê¾÷ºc¤~ª¾¹D¡H¡H¡H
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/17 ¤U¤È 01:45:57
²Ä 6600 ½g¦^À³
|
¤p©ú¤j ¹L«×¼ÖÆ[»P¹L«×´dÆ[³£¬O«D²z©Ê·Qªk¡A¦³¦h¤Ö¼Æ¾Ú»¡¦h¤Ö¸Ü¡A¤j®a·Q£¸·QTREK-DX »PTREK-AD 昰¤£¬O¬Û¤¬½÷¬M¡A¬Û¤¬±Ï´©¡ATREK-AD¤C¤ëªìªº¼Æ¾Ú¹ï·Ó²Õ¤ñ¹w´ÁÁÙ¦n¡A¸g¹L¦¸²Õ¸s¤ÀªR²×©ó§ä¨ì¦¬®×ÄY®æ¤~¯à¯u¥¿¤ÏÀ³¨â²Õªº®t¶Z¡ATREK-DX ©Û¶Ò75¦W¡A¥ß§Y§ó§ï¦¬®×¼Ð·Ç¡Aªì¨B22¤H¼Æ¾ÚÃÒ ©ú¨ä¥O¤HÅåÆvªºÀø®Ä¡A22¤H¥ÎÃIJÕ昰¤°»ò·N«ä¡A ³o¦¸¦¬®×75¤H¡A¹êÅç²Õ50¤H¡A¹ï·Ó²Õ25¤H 22¤H\50¤H¡A¤½§i¼Æ¾Ú±µªñ¦Ê¤À¤§45¡A§Ö£¸¥b¤F¡A³o¨Ç¨Ï¥ÎDuplicub ¨S®Ä©Î¬O°Æ§@¥Î©Î¬O¨ä¥L¦]¯ÀÂ÷¶}ªº¯f±w¡A³o¸sÃøªvªº¯f±w¨Ï¥ÎASLAN004 16¶g ¨C¶g400mg¾¯¶q²£¥Í¥O¤H ¦L¶H²`¨èªºÀø®Ä»P¦w¥þ©Ê¡ATRED-DX ÃÒ©úTRED AD¥ý«eªº°²³]¦¬®×ÁÍÄY®æªº¥¿½T©Ê¡A³o¬O£¸Ó±µ¤OÁÉ¡A«e±Áö±¼´Î¡A«á±°¨¤W°l»°¤W¨Ó¡AÀHµÛ¼Ú¬ü§ó§ï¦¬®×¤è¦¡¡A¦~©³¼Æ¾Ú¤£·|®t¤Ó¦h¡AÁÙ®t¦Ê¤À¤§55¥ÎÃIJռƾڡAÀR«Ý¦~¤¤»P¦~©³¼Æ¾Ú¡A ²{¦bÁ`¥«È¤~£¸¤d¦h¸U¬ü¤¸¡A¤£©ÈªÑ¥»¼W¥[£¸¨Ç¡A¤]¤£ª¾¹D¦³¦h¤ÖªÑn³¬Âꤦ~¡H¯u¥¿¼W¥[¤]¬O¦³¡AÀø®Ä»P¨ÖÁʩαÂÅv¤µÃB¤~¬O³Ì«nªº ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/16 ¤U¤È 05:43:27
²Ä 6599 ½g¦^À³
|
¥xÁÞ¤j¡A
§A«Ü¥Î¥\¨Ã«O«ù¼ÖÆ[¡A
¦ý§ÚÁÙ¬O¤£¬Ý¦n¡AÁöµM§Ú¤]¤£½æªÑ¤F¡A´N·í½ä³Õ¿é嘞¡A
¸Ó¤½¥qªº¸Û«H¤£¨Î¡A¦h¦¸©ó¸Ñª¼µo¥¬¼ÖÆ[°T®§¡A
¸Ñª¼«á´N«æ³t¼É¶^¡A¹ï¤½¥qªº®ø®§§Ú¬O¤£·|¬Û«H¤F¡A
¦A»¡¦pªG¦³¤½¥q©Ò»¡¡ATREK-DX¸ÕÅ禳¦¨®Ä¡A ¡A ¦ÛµM·|¦³±M®a¬ã¨s¨ä¦¨®Ä¡A
¤½¥q¬°¦ó¥uº¦¤@¤Ñ´N«æµÛ½â½æªÑ²¼¨p¶Ò¡A
³o¤£²Å¦XÅÞ¿è¡A
¦Ó¥B¤Ñ©R¤j¤wÂ÷¶}¥»ª©¤@¦~¡A¤]³\¦¤w¥X²MªÑ²¼¡A
¥Lªº½×z¤]¤w¨Æ¹L¹Ò¾E¡A¦A¤Þz¥i¯à¤£©y¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/15 ¤U¤È 09:08:12
²Ä 6598 ½g¦^À³
|
§ó¥¿ ¤Ñ©R¤j¥h¦~¤»¤ë¤G¤Q¤T¤é¹ïASLAN 004²§¦ì©Ê¥Ö½§ª¢±ÂÅv¹w¦ôÈ¡A¥Dn昰®Ú¾Ú¤é¥»ÃÄ«~¥«³õ ¦û¤ñ±À¦ô¥þ²y¥«³õ±ÂÅvª÷(¤£¥]¬AASLAN003¯Z¨r) ȱo¤j®a参¦Ò¡A¨º®ÉÔ©|¥¼¤½§GTREK-DX ¥O¤HÅåÆvªºªì¨B¼Æ¾Ú
¸É¥R 1 TREK-DX Àu²§ªºªì¨B¼Æ¾Ú¨Ó¦Û©óTREK-AD ªº¦¸±Ú¸s¤ÀªR, ¨Ã§Ö³t½Õ¾ã¦¬®×ÁͦVÄY®æ¼Ð·Ç ªºµ¦²¤(¼Ú¬ü¦P¨BÁͦVÄY®æ)TREK-DX »P EblasaKimab in Atopic Dermatitis TREK-AD ¦P¨BÁͦVÄY®æ¦¬®×
2 FAST-AA ¬ã¨s¡A¹wp¸Ó¬ã¨sªº¤¤´Áµ²ªG±N©ó 2024 ¦~¤¤¤½§G, ªÎ¤ô¤£¸¨¥~¤H¥Ð»°§Ö¥Ó½Ð±M§Q«OÅ@ (ªø¹F20¦~)
3 ASLAN Pharmaceuticals °õ¦æªø Carl Firth ³Õ¤h»¡¡C ¡u§ÚÌ«Ü°ª¿³¦¬¨ì¼Ú¬w±M§Q§½Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¥¿±ªì¨B·N¨£¡A¨Ã»{¥i§ÚÌ©Ò¦³ ªºÅv§Qn¨D§¡¨ã¦³·s¿o©Ê©M³Ð³y©Ê¡C¦pªG¦b°ê®a¶¥¬qÀò±o±ÂÅv¡A·s±M§Q±N§âfarudodstatªº±M§Q«OÅ@ ©µªø¦Ü¦Ü¤Ö2043¦~¡C³o±NÅãµÛ¼W±jfarudodstatªº°Ó·~¿W¦û©Ê¡A¬O§Ú̦b©Ò¦³ÃöÁä°Ó·~»â°ìfarudodstat ¥[±j ¥Ñ©ó´³¨r±wªÌ¥i¥ÎªºªvÀø¿ï¾Ü«Ü¤Ö¡A§Ú̪º¥Ø¼Ð¬O¬°±wªÌ´£¨Ñ¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/15 ¤U¤È 08:30:14
²Ä 6597 ½g¦^À³
|
¤Ñ©R¤j¥h¦~¤»¤ë¤G¤Q¤T¤é¹ïASLAN 004²§¦ì©Ê¥Ö½§ª¢±ÂÅv¹w¦ôÈ¡A¥un昰®Ú¾Ú¤é¥»Ãħ½¥«³õ¦û¤ñ±À¦ô¥þ²y¥«³õ±ÂÅvª÷¡A(¤£¥]¬AASLAN003¯Z¨r) ȱo¤j®a参¦Ò¡A¨º®ÉÔ©|¥¼¤½§GTREK-DX¥O¤HÅåÆvªº¼Æ¾Ú
¥H¤U¬O¤Ñ©R¤j¹w¦ô
ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô
¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸.
¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸----B
C=B-A=27.7»õ¬ü¤¸-7.8»õ¬ü¤¸(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»«á¤§§Q¯q)
¤@¤@¤@¤@¤@ASLN004 ¤§»ùÈ:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í¤@¤@¤@¤@
⋯¡]¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q)
¥H¤W¥¼§tASLAN003ªº»ùÈ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/14 ¤U¤È 07:53:27
²Ä 6596 ½g¦^À³
|
³o¤@¦¸¬O¨p¶Ò500¸UªÑADS¡]¨p¶Ò»ù1¤¸¡^¦A¥[¤W500¸UªÑªº»{ªÑÅvÃÒ¡]»{ÁÊ»ù1¤¸¡^¡A»{ªÑÅvÃÒ5¦~«á¨ì´Á¡A»{ªÑÅvÃÒ´N¥b¶R¥b¬Û°e¤£¥t¦¬Åv§Qª÷ª½±µµ¹¨p¶Òªº¤H¤F¡AÁ`¦¬¤J¬°467.5¸U¬ü¤¸¡An¬O»{ªÑÅvÃÒ¥þ³¡¦æ¨Ï¡AªÑ¥»ª½±µ¿±µÈ6¦¨¥H¤W¡AÁ`¦¬¯qºâ967.5¸U¬ü¤¸¦n¤F¡A¦U¦ì»{¬°³o°Ï°Ï967.5¸U¬ü¤¸±Ï±o¤Faslan?¬JµM³oµ§¿ú¤w¸gµLÃö¥G¤j§½¡A¤S¬°¦ónÅýªÑ¥»¿±µÈ6¦¨¡H¡H¡H³o´N¬O©Ò¿×ªº¨ÖÁʤj®v¡H¡H¡H¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/13 ¤U¤È 09:27:06
²Ä 6595 ½g¦^À³
|
«Ó°¶¤j»¡ªº¨S¿ù¡AªGµM¤Þ°_§ë¸ê¾÷ºc zacks investment research ªºª`·N ¥Zµn¤½¥q¤½§i¸ê°T¥þ¤å¡A¥i·j´M ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
March 12, 2024 ¡X 09:58 am EDT
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/13 ¤U¤È 08:53:29
²Ä 6594 ½g¦^À³
|
¦U¦ì·à¤Í¯u¬O¨üºÉ§é¿i¤F¡A
§ÚÓ¤H»{¬°¡A
¤½¥q¨p¶Ò5¦Ê¸UªÑ¡Aq»ù1¬üª÷¡A
¥æ©ö¤é3¤ë14¤é¡A¤¦~«á¤~¨ì´Á¡A
¥Ø«eªÑ»ù§C©ó1¤¸¡A¦pªG©ú¤Ñ¤´¯à¨Ì¬ù§¹¦¨¥æ©ö¡A
§Ú·Q¤½¥q¤§¥Øªº¡A¬OÅýªÑ»ù¦b6¤ë©³«eºû«ù¦b1¬üª÷¤§¤W¡A
ºû«ùÄ~Äò¦bNASDAQªº¥æ©ö¤è¦¡¡A
¨Ã¥Bª§¨ú¤@¨ÇÎA©µ´Ý³Ýªº®É¶¡¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/13 ¤U¤È 07:51:12
²Ä 6593 ½g¦^À³
|
¼ÖÆ[¥J¯uªº«Ü¼F®`¡A¥un·h¥X¥«³õ¼ç¤O«Ü¤j¡AµeÓ¤j»æ´N¥i¥H¹L¤é¤lªº·Pı¡A§Y¨ÏCOPD¡BAA¤G´Á®Ú¥»¤°»ò¨M©w©Êªºµ²ªG³£ÁÙ¨S¥X¨Ó´N¥i¥H±·¦¨³o¼Ë¡A¥t¥~ÁÙ¦³µêµLÄÆ´ùªº¥D¤OÀ£§CªÑ»ù¦Y³f»¡ªk¤]¬O¤@µ´¡A°ò¥»¤W«ùªÑ¶W¹L5%´Nn¥Ó³ø¤F¡A¨ì²{¦b³Ìªñ¥Ó³øªº¤]´NBVF,K2¸òUBS¡A³o¤G¤Ñ¶gÂà²v¤j·§¬ù180%¸ò90%¡A¦pªG³o´X¤Ñ¨S¦³¥Ó³ø«ùªÑ¶W¹L5%ªº·s¤jªÑªF¡A´Nª¾¹D¼ÖÆ[¥J̪º¥D¤O´N¬O¯º¸Ü¤@«h¡A¨ì©³þ¸Ì¨Óªº¼oª«¥D¤O³sÄò¤G¤Ñ¶gÂà²v³o»ò°ªÁÙ¦¬¤£¨ì¶W¹L5%Äw½X¡A¦Ó¥B¥HAslan¥«È1»õ¬ü¤¸¡]ªÑ»ù¬ù6¬ü¤¸¡^¨Ó»¡¡A5%¥«È¤]¤~500¸U¬ü¡A§ó¦óªp±q2024¦~1¤ë¥H¨Ó¡AªÑ»ùªø´Á¦b0.5¬ü¤¸¥ª¥k¡A5%«ùªÑ¤]¤~¤£¨ì50¸U¬ü¤¸¡A¨ì©³¬OþÓ¼oª«¥D¤O³s50¸U¬ü³£¶R¤£°_°Õ¡AÃø¤£¦¨³o°¶¤jªº¥D¤OnÀ£§C¨ì0.05Ä~Äò¦Y³f¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§_¨ì©³°Õ10148994 |
µoªí®É¶¡:2024/3/13 ¤U¤È 07:06:00
²Ä 6592 ½g¦^À³
|
m.investing.com/news/stock-market-news/aslan-pharmaceuticals-announces-5-million-offering-93CH-3334785 ¥i¥ß§Y¦æ¨Ï¡A¤¦~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/3/13 ¤U¤È 02:32:58
²Ä 6591 ½g¦^À³
|
¥ý¤£ºÞªÑ»ù¤S¦^¨ììÂI ¦Ü¤Ö¶q¦³ª£¥X¨Ó¡AÅý¤j®aÃöª`¨ì´N¬O¦n¨Æ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/3/13 ¤U¤È 01:47:47
²Ä 6590 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j
¬üªÑ¨p¶ÒªÑ²¼ ¦³³¬Âê´Á¶Ü¡H ¦³ªº¸Ü ¦h¤[¡H
½Ðª¾¹Dªº¤j¤j ½ç±Ð |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/13 ¤U¤È 01:09:30
²Ä 6589 ½g¦^À³
|
ªº½T´²¤áªº®zÂI´N¬O¬Ý¨£ªÑ»ù¶^ªº®ÉÔ·|¶°Å鮣·W½æ¥X«ùªÑ , ¤W¨R¤U¬~®É¤£°í©wªºÄw½X ³vº¥¸¨¤J¤jªÑªF¤â¤W, ¨ä¹ê´N¬O¥H¤j´Û¤p ( ¤jªÑªF¤â¤W¦³ªÑ²¼ ¤S¦³²{ª÷ ) µ¥¬y³qÄw§l¦¬¹L¥b®ÉªÑ»ù©Ô©ï°_¨Óªý¤OÅܤp ( ¯d¤Uªº´²¤á³£¬O°í©wªºÄw½X) ªÑ»ù¤~¦³¯u¥¿ªº¤W¤É
¤jªÑªFÁöµM¾Ô³NÆF¬¡¿W¥ß©Î¦X¤O©Ô©ïªÑ»ù µL©¹¤£§Q , ´²¤á¯u¥¿nÃö¤ßªº°£¤FªÑ»ù ¨ÖÁÊ»ù¥~¬O¾Ô²¤ªº¥¿½T ¤]´N¬O¤½¥q¶}µo²£«~¬O§_¨ã¦³Àø®Ä»P¦w¥þ©Ê ¶}µo²£«~ªººØÃþ»P¥«³õ¤j¤p , ¥»¦¸¶Ò¸ê500¸U¬ü¤¸¥Dn¥Î©ó ¸ê§U·sªº©M¨ä¥L¥¿¦b¶i¦æªº¬ãµo¬¡°Ê¡BÀç¹B¸êª÷©M¨ä¥L¤@¯ë¤½¥q¥Î³~, ¯à¶Ò¨ì¸êª÷³Ì«n ,¦³¸êª÷¤~¦³ «áºüªº¬ãµo, ·í²£«~½u¦h¤¸¤S¦³Ävª§¼ç¤O¥¼¨Ó³Q¨ÖÁÊ»ù¤~·|°ª, ´²¤á»P¨äÃö¤ßªÑ»ù¤£¦pÃö¤ß¨ÖÁÊ»ù
ÁÉ¿Õµá¡B¦A¥Í¤¸ ÀHµÛºC©Êªý¶ë©ÊªÍ¯fªºÂX±i¡A¾P°âÃB¥¼¨Ó¥i¯à¹F¨ì 20B ¬ü¤¸°ª®p , 2023¦~ ¬ù115.9 »õ¬ü¤¸ ( Dupixent global net sales soared by 33% to $11.59 billion in 2023)
¨Ì¾Ú¤½¥q¤½§i¼Æ¾Ú 63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§ ¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î ±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À¹F¨ì0©Î1¡A ¦Ê¤À¤§81.5ªº¯f±w¨Ï¥ÎÀø®ÕµLªkªø´Á¹F¨ìIGAµû¤À¹F¨ì0©Î1,³o¬O£¸Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡A ¤]¬Oeblasakimab ¤d¸üÃø³{ªº¾÷·| ( Eblasakimab °£¤FTREK-AD »Pdupilumab¥¿±¹ï¨M¥~ ,¨Ï¥Î¹Ldupilumab Àø®Ä¤í¨ÎªÌªº¥«³õ¤]«ÜÃe¤j, ¥i¥H¤j¤O·m§ð ¥t¥~ÁÙ¦³¦Ê»õ¬ü¤¸¥«³õªº fast-AA COPD )
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/3/13 ¤W¤È 11:52:30
²Ä 6588 ½g¦^À³
|
±±½L©ó§_¹ï§b·à¦Ó¨¥¡A¬Oµu½u½Ä®ö«ÈªºÃöª`¡FµM³o¤½¥qY¨S¦³¨ÖÁʪº°Ê¦V¬O¨S¦³ªø»·¤U¤@¨Bªº¡A¤j®an²`«×«ä¼{¦p¤T´Ánªá¦h¤Ö¿ú?´Nª¾¹Dªü·à¥¼¨Ón«ç»ò¿ì¤F?
¤j®a°Ñ¦Ò¡A¬ÕÁ«¦Ût~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2024/3/13 ¤W¤È 09:35:39
²Ä 6587 ½g¦^À³
|
5M ªÑADS¨p¶Ò¡A¬ù¦ûÁ`ªÑ¥»16.7M ¤§3¦¨¡A¤ñ¨Ò«Ü°ª ---------------------------------------------------------------
ÉÜ®a¤£±±盘
ÉÜ®a¤£±±盘¤@¥uªÑ²¼·N¨ýþÓÉÜ®a§C¤_这²¼ªº10%ªº¬y³q筹码¡AÉÜ®a¤â¤¤¤£¨¬10%ªº¬y³q筹码谈¤£¤W±±盘状态¡A¥u¯à说¬O¤@个¤¤¤j户¦Ó¤w!
轻«×±±盘
ÉÜ®a¯à轻«×±±盘¤@¥u个ªÑªº话¤â¤¤个ªÑ³Ì°_码¦³20%¦Ü30%¥ª¥kªº¬y³q筹码¡A这30%ªº¬y³q筹码³£¬O随Éó·t¤¤§C§lªº;³£¬O¾a´²户卖¥XªÑ²¼¡AÉÜ®a¬Ý¦n这²¼¡A³v渐§C§l¦Ó来ªº¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/13 ¤W¤È 08:57:25
²Ä 6586 ½g¦^À³
|
5M ªÑADS¨p¶Ò¡A¬ù¦ûÁ`ªÑ¥»16.7M ¤§3¦¨¡A¤ñ¨Ò«Ü°ª
¦Ó¥Bq»ù1¬üª÷¡AÁ`¶Ò¸ê¤~500¸U¬üª÷¡AÁÙnµ¹¥N²z°Ó¶Äª÷¡A
¹ê®³¤£¨ì500¸U¬üª÷¡A¦p¦¹¾Þ§@¥i¯à¤w¤s½a¤ôºÉ¡A«æ»Ý¥Î¿ú¤S§ä¤£¨ì¿ú¡A
³oªü¤TCEO±q¦b¥xÆW´NJ§@«D¬°¡A±q¤£¦Ò¼{ªÑªF§Q¯q¡A
¦pªG®Ä¥Î¤ñ§ù¥²ª¢¦n¡A¦ÛµM·|¦³¤H¶R³æ¡A¨º¤S¬°¦ó¤~º¦¤@ÂI´N«æµÛ½æ¿ú¡A
¦A¥Í¤¸ªÑ»ù²{¤w9¦Ê¦h¬üª÷¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2024/3/13 ¤W¤È 08:47:36
²Ä 6585 ½g¦^À³
|
§ë¸ê·sÃĥͧÞÁÙ¬OÃöª`¦b¨ä¦¨¥\²v»PÃÄ«~¥«³õ. ¤pªÑªF¦h¤£³ßÅw§CªÑ»ù¡A¤£¹L§CªÑ»ù¦³§Q©ó²ø®a! 1.¤@ª÷¿Ä¤k³Õ¤h说¯}ªÑ¥«¡G为¤°¤\ÉÜ®a´±¥´压ªÑɲ¡AúÒ¤£©È别¤H抢·Gɲ筹码¡H xueqiu.com/6895810792/146076771
2.¨p¶Ò¾Þ½L¤â³zÅS¡G²ø®a«Øܤâªk¥þ§ð²¤ news.cnyes.com/news/id/1154883 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/3/13 ¤W¤È 08:06:04
²Ä 6584 ½g¦^À³
|
·í®É004 ¦b¤@´Áªì
³o¦¸¤G´Á¤w°µ§¹ ·Ç³Æ¤T´Á ÁÙ¦h°µ¤F¦³«Ø³]©Êªº¸ÕÅç
·íªì4 ¤¸¨p¶Ò ªÑ»ù«æ©Ô¨ì8 ¤¸ »¤¾É¾÷ºc°Ñ¥[¨p¶Ò
³o¦¸ªÑ»ù¼ÆÓ¤ë¤@ª½¦b 1 ¤¸¥H¤U °Ñ¥[ªÌÄ@·N¥H 1 ¤¸ÁʤJ
¨p¶ÒÀ³¸Ó¬O«æ©Ô¨ì2 ¤¸ ¤§«e´N½Í¦n¤F ¤½¥¬¨p¶Ò®ø®§«á «æ®À¦^°_ötÂI¡]0.62¡^¤W¤@ÂIÂI
À£¦^¤~¬O¹ïªº ¤£µM ª½öt¤W¥h °Z¤£¬O¦³¤º½u¥æ©ö¤§¶û
500 ¸U¬ü¤¸ªº¨p¶Ò¤£ºâ¤jµ§ ¬°¦ó¦³¾÷ºcn¥Î1 ¤¸°Ñ¥[³o¨p¶Ò
«áÄò ªÑ»ù¦p¨S¦A¤U¦æ ÅuµP®ÉÔ¨ì¤F
@¤H´M¨ý
@¤H´M¨ý
@¤H´M¨ý
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/13 ¤W¤È 04:34:51
²Ä 6583 ½g¦^À³
|
ªGµM³Q§Ú§¹¥þ©R¤¤¡A¸òaslan004¤@´Áµo¥¬ªì´Á¼Æ¾Úªº®ÉÔ§¹¥þ¤@¼Ë¡A´N¥u¬O¬°¤F¨p¶Ò½Ä°ª»ù®æ¦Ó¤w¡]¤§«eµo¥¬«á½L«e½Ä°ª¨ìUSD8¤¸¡AµM«á¤]¬Oª½±µUSD4¤¸¥ª¥k¨p¶Ò¡AªÑ»ùª½±µ±YÄê¡^¡A³o¦¸¤]¬OµoÓªì´Á¥¼¸Ñª¼¼Æ¾Ú¡A½Ä°ª»ù®æ«á¥ß¨è§C»ù¨p¶Ò¡AµM«áªÑ»ùª½±µ±YÄê¡A¾ú¥vÁ`¬OÅå¤Hªº¬Û¦ü¡A¤w¸g¤Wºt³o»ò¦h¦¸¤F¡AÁÙ¬O¦³¤H¿ï¾ÜµLµø¡A¦³¤HÁ`¬O¤@ª½¦b»¡carl firth¬O¨ÖÁÊ°ª¤â¡A½Ð°Ý¥i¥H§ä¥X¤@Ó¨Ò¤lµ¹¤j®aÁ@Á@¡A¨Ó¬Ý¬Ý¨ì©³¦h·|¨ÖÁÊ¡H§Ú¥uª¾¹D¬OÓ°é¿ú°ª¤â¦Ó¤w¡A«ö·Ó¤W¦¸¸gÅç¡A±µ¤U¨ÓªÑ²¼·|«ùÄò½w¶^«Üªø¤@¬q®É¶¡¡A¦Ó¥BªÑ¥»¤]¶}©lºCºC¿±µÈ¤¤¤F¡A¦Ñ·à¤Í̽ЫO«¡A§O¦A¬Û«H¨º¨Ç¼ÖÆ[¥J¤F¡A¤j®a¥i¥H¥h½½Â¤å¡A´N¥i¥Hª¾¹D¼ÖÆ[¥Jªº¤ÀªR°ò¥»¤W¨S¦³·Ç¹LRRR¡AˬO§Úµo¤å´£¿ô¤j®aª`·N¡A¼ÖÆ[¥JÁÙ¤£¼Ö¨£¡A¨ì©³¬O½Ö©~¤ß¥r´ú©O¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/12 ¤U¤È 11:41:05
²Ä 6582 ½g¦^À³
|
ªGµM¤@¦p¬J©¹¡A¬Q¤Ñ¤£ºÞ¬O½Ö©Ô°ªªº¡A¤W2¤¸«áª½±µ¤@®Ú¤j¶ÂK¥X³f¡A¥u³Ñ°l°ªªº®M¦b¤s³»¡A¬Ý¬Ý±q2¤¸¨º¤@®Ú±þ¤U¨Ó¤§«á¡A¦¨¥æ¶q¾ãÓµäÁY¡A´Nª¾¹D¬Q¤Ñ©Ô°ªªº¥D¤O¦¶]¤F¡A¥u³Ñ´²¤áú·w¦b´Z©Ò¡AµM«á´N¥u¯àÄ~Äò½w¶^¤F¡A¨C¦¸Aslan¦³´Á¤¤¼Æ¾Ú¤½¥¬³£·|¨Ó³o¤@©Û¡A¯uªº¼Æ¾ÚÀu¨q¡A«ç»ò·|¬Q¤Ñ½L«e´X¥G¨S¤ÏÀ³¡Aª½¨ì½L¤¤¤~¶}©l©Ô¡A´N¬O·íµu½uª£¤@ªi¡A¶¶«KÅý¼ÖÆ[¥J¦í®M©Ð¡A¦Ñ·à¤ÍÀ³¸Ó³£«Ü¼ô±x³o®M¸ô¤F..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/3/12 ¤U¤È 10:00:55
²Ä 6581 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/12 ¤U¤È 09:28:06
²Ä 6580 ½g¦^À³
|
ASLAN Pharmaceuticals ¸g¾ú³sÄòÁ{§É¥¢§Q¦p¤µWºÉ¥Ì¨Ó¡A°t¦Xªñ´ÁÁ{§É¼Æ¾Úªºµo§G¡A ªÑ»ù§Þ³N½u«¬§Î¦¨¦hÀY±Æ¦Cªº±j¯P¶R¶i°T¸¹¡A ªÑ»ù·|»¡¸Ü¡Aªñ´XÓ¤ë¥kÃä¤j¶q¦Y±¼¥ªÃä¶q¡A ³oºØ¼Qµo¤Wº¦¤è¦¡¨M«D´²¤á©Ò¬°¡AÁÙ¨S¤W¨® ªº¤j¤jµ¥®É¾÷¤W¨®¡A¤£¥Î¦Ç¤ß¡C ²Ö¿n¨ÖÁʽͧP¹ê¤O : TREK-DX :(ªñ¤é¤wµo§G22¤H´¿¨Ï¥Î¹L dupilumab ªº±wªÌ¤¤Âà¨Ï¥ÎeblasakimabªºÀø®Ä¼Æ¾Ú) 63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À¹F¨ì0©Î1¡A³o¬O£¸Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡A¤]¬Oeblasakimab ¤d¸üÃø³{ªº¾÷·|¡C
TREK-AD : TREK-AD ¬ã¨sªºµ²ªGªí©ú¡Aeblasakimab ¦³¼ç¤O¦b²§¦ì©Ê¥Ö½§ª¢ (AD) ¤¤´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¦Ó¤£¼vÅT Àø®Ä¡A¨Ã¦¨¬° AD ªº»â¥ýÀøªk
FAST-AA : (´Á«Ý¦~¤¤µo§G´³¨r¬ã¨sªº´Á¤¤¼Æ¾Ú)
¨ä¥L¦³¼ç¤Oªº»â°ì COPD : (ºC©Êªý¶ë©ÊªÍ¯f ´Á«Ýªñ´Á°ê»Ú´Á¥Z¬ã¨sªº¶i¤@¨B¼Æ¾Ú )
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/3/12 ¤U¤È 06:13:49
²Ä 6579 ½g¦^À³
|
¨Ì·ÓAslanªººD¨Ò¡A³£·|¥ý¤½¥¬³¡¤ÀÀø®Ä¬Ý°_¨Ó«ÜÀu¨qªº¼Æ¾Ú¡AµM«á§Q¦h¶}©l¥XÅ¢¡AÀHµÛªÑ»ù¦bµ²ªG¤½¥¬«e¤i¹F¨ì°ªÂI¡AµM«áµ²ªG¥X¨Ó¤£¦p¹w´Á¡Aª½±µ¥´¦^ì§Î¡A¬Ý¬ÝAslan001¡A»¡ªºÃĮĦh¦n¦h¦³«H¤ß¡Aª¼¼Æ¾Ú¤]¬O»¡¦h¦n¦h¦n¡Aµ²ªG¸Ñª¼«á¤£ºÞ¬O¸~½F¤ÏÀ³²vÁÙ¬O¦s¬¡´Á¡A³£¸ò¦w¼¢¾¯²Õ®t¤£¦h¡A¨ì©³þ¸Ì¨Óªº«H¤ß¡HAslan004¤]¬O¤@´Á³¡¤À¼Æ¾Ú«ÜÀu¨q¡Aµ²ªG§¹¾ãµ²ªG¥X¨Ó¤]¬O¾ãÅéÀø®Ä¤£¦p¤@°_ªì´Á¼Æ¾Ú¡A¤G´Á¤]¬Oµ²ªG¥X¨Ó¤~¦A»¡¦w¼¢¾¯²Õ¤ÏÀ³²v¤]«Ü°ª¡A¤§«áªÑ»ù´N±Y½L¤F¡A«e¦¸¶gÂà²v¯}¦Ê´N¬O¤@´Áªì´Á¼Æ¾Ú¥X¨Ó¡AµM«áªÑ»ù¶}°ª«á¤½¥q¥ß¨èµo¥¬¨p¶Ò¡AµM«á¤@¸ô±YÄê¡A·íªì¨p¶Ò¶i¨Óªº¥þ³¡®M¦º¡AAslan¤£¯Êµe¤j»æªº¯à¤O¡A»æµeªº¦A¤j¡A¤´Â¤ñ¤£¤W³Ì«áªº¹êÅçµ²ªG¡A³oºØ´Á¤¤¼Æ¾Ú°Ñ¦Ò´N¦n¡A¦Ñ·à¤ÍÌÀ³¸Ó¤w¸g§K¬Ì¤F..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/3/12 ¤U¤È 05:27:43
²Ä 6578 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/12 ¤W¤È 08:15:08
²Ä 6577 ½g¦^À³
|
¬Q±ß¦¨¥æ¶q¬O¾ú¥v¤W³Ì¤j¶q¡A
§CÀÉ¥X¤j¶qÀ³¬O¦n¨Æ¡A
¦ý³o¶q¤]¤ÓÅå¤H¤F¡A ¸Ó¦p¦ó¸ÑŪ¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/12 ¤W¤È 08:01:12
²Ä 6576 ½g¦^À³
|
¦U¦ì¤j¤j
¨È·à±dªÑ²¼Á`¶q¦³16.7MªÑ¡A
¥i¬O¬Q¤Ñªº¦¨¥æ¶q25.2MªÑ¡A
µ¥©ó¬O©Ò¦³ªÑ²¼³£³Q½æ¹L1¦¸¥H¤W¡A
³o¶q¬O§_¥¿½T©O¡A
´X¥G©Ò¦³ªÑ²¼³£´«¤H©Î¬O¦h¦¸¶R½æ¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/12 ¤W¤È 12:08:57
²Ä 6575 ½g¦^À³
|
§ó¥¿¸É¥R TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦óì¦]°±¤î dupilumab ªvÀøªº±wªÌ¡A¥]¬AAD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Îµo¥Í¤£¨}¨Æ¥ó¡A¨Ã¥H 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¨C¶g¤@¦¸¡A«ùÄò 16 ¶g¡C ¦b¹ï 22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬dªº¼Æ¾ÚºI¤î®É ®Ú¾Ú³Ìªìªº¯Ç¤J¼Ð·Ç¤J²Õ¡A¥H 2:1 ªº¤ñ¨ÒÀH¾÷¤À°t¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A17 ¦W±wªÌ§¹¦¨¤F 16¶gªvÀø´Á¡A5 ¦W±wªÌ¦b 16 ¶gªvÀø´Á§¹¦¨«e°±ÃÄ¡C 10 ¦W±wªÌ¡]§Y 45%¡^ªº EASI ¤À¼Æ¤U°¦Ü¤Ö 90¡]EASI-90¡^¡A11 ¦W±wªÌ¡]§Y 50%¡^ Àò±o¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô (vIGA) ¤À¼Æ 0 ©Î 1¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^¡C 9¦W±wªÌ¤¤¦b¥ý«e¹ï dupilumab ¤ÏÀ³¤£¨¬ªº±wªÌ¤¤¡A5 ¦W±wªÌ (56%) ¹F¨ì EASI-90¡A5 ¦W±wªÌ (56%) ¹F¨ì vIGA µû¤À¬° 0 ©Î 1¡C¨´¤µ¬°¤î¡AªvÀøªº@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C ¨S¦³µ²½¤ª¢ªº³ø§i¡A¤]¨S¦³µù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C ¨Ó¦Û§¹¾ã¼Æ¾Ú¶°ªº³Ì«nªº«Dª¼¼Æ¾Ú ¹wp2024¦~©³¡C ¡u63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^2 ¡A ©M¤j¬ù¤@¥bªº±wªÌ½T¹ê¹F¨ì¤F³oºØ¤ÏÀ³¡A¦ý¦b±µ¤U¨Óªº 36 ¶g«á¨Ã¨S¦³ºû«ù³oºØ¤ÏÀ³ ¡A©Ò¥H¦³¢¤Á»ÝnÃB¥~ªº¥Íª«Àøªk¨Ó´£¨Ñ¦w¥þ¦³®Äªºªø´ÁªvÀø¥¼¹F¨ì¨¬°÷¤ÏÀ³ªº±wªÌªº¿ï¾Ü¡C
Ó¤Hµû½× 63% ±µ¨ü dupilumab ªvÀøªº±wªÌ¦b 16 ¶g«á¥¼¯à¹ê²{³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬° 0 ©Î 1¡^¡Aªí¥Ü¥u¦³37¢Hªº¯f±w¹F¼Ð¡A¹F¼Ð¤¤¤S¦³£¸¥bµLªk¦b±µ¤U¨Ó36¶gºû«ù³z©ú©Î±µªñ³z©úªº¥Ö½§¡A¤]´N¬O»¡¥u¦³¦Ê¤À¤§18.5ªº¯f±w¨Ï¥Îdupilumab¯à¯u¥¿ªº¹F¨ìIGAµû¤À ¹F¨ì0©Î1¡A³o¬O£¸Ó«Ü¤j¥¼³Qº¡¨¬ªº»Ý¨D¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/11 ¤U¤È 11:13:41
²Ä 6574 ½g¦^À³
|
Dupilumab experienced 22¤Hªì¨B¼Æ¾Ú ¶W¥G¹w´Áªº¦n ( Dupilumab Àø®Õ ¤í¨Î¤¤¤S±Ï¤F45%-50 % ªº¤H )
(10¤H/22¤H 45% ¹F¨ì EASI 90 11¤H/22¤H 50% ¹F¨ì vIGA¤À¼Æ 0 ©Î 1 (EASI 75 ¼Æ¾Ú·|¤ñEASI 90 §ó¦n)
(¨ÖÁÊ»ù®æ´£¤É 1 AD ¤G B¼Æ¾Ú 2 ¦~¤¤AA ¼Æ¾Ú 3 TREK-DX¼Æ¾Ú ( ´£¦¤½§i75¤H¤¤ªº22¤H )
¤µ¤é°T®§«Üªø «ÂI¦p¤U TREK-DX ¯Ç¤J¼Ð·Ç¤w¦¬ºò¼Ð·Ç¡A©Û¶Ò°ò½uÀã¯l±¿n©MÄY«µ{«×«ü¼Æ (EASI) µû¤À¦Ü¤Ö¬° 18 ¤À ¡]¦Ó¤£¬O 16 ¤À¡^ªº±wªÌ¡C¦P®É¡A¤]¹ê¬I¤F¿W¥ßµû¼fû¹ï°ò½u EASI ¤À¼Æªº½T»{¡C ¬ü°êºô¯¸¥Ø«e¥¿¦b®Ú¾Ú§ó·sªº¼Ð·Ç©Û¶Ò±wªÌ¡A¼Ú¬wªº¨ä¥L¯¸ÂI¤]¹wp¦b¼Ú¬w¶}©ñ2024 ¦~¤W¥b¦~¡C TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦óì¦]°±¤î dupilumab ªvÀøªº±wªÌ¡A¥]¬AAD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Îµo¥Í¤£¨}¨Æ¥ó¡A¨Ã¥H 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¨C¶g¤@¦¸¡A«ùÄò 16 ¶g¡C ¦b¹ï 22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬dªº¼Æ¾ÚºI¤î®É®Ú¾Ú³Ìªìªº¯Ç¤J¼Ð·Ç¤J²Õ¡A¥H 2:1 ªº¤ñ¨ÒÀH¾÷¤À°t¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A17 ¦W±wªÌ§¹¦¨¤F 16¶gªvÀø´Á¡A5 ¦W±wªÌ¦b 16 ¶gªvÀø´Á§¹¦¨«e°±ÃÄ
10 ¦W±wªÌ¡]§Y 45%¡^ªº EASI µû¤À¤U°¦Ü¤Ö 90%¡]EASI-90¡^
11 ¦W±wªÌ¡]§Y 50%¡^Àò±o¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô (vIGA) ¤À¼Æ 0 ©Î 1
¨´¤µ¬°¤î¡AªvÀøªº@¨ü©Ê¨}¦n¡A¨S¦³µo²{·sªº¦w¥þ°T¸¹¡C
Dupilumab experienced(½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w) ¤j®a·Q¤@·Q TREX-DX ¹êÅç¼Æ¾Ú¬OÀø®Ä¤ñ¸û«n ÁÙ¬O¦¤@ÂI¤½§i¼Æ¾Ú¤ñ¸û«n ? ¤½¥q½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡¬O¥¿½Tªº¿ï¾Ü
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/11 ¤U¤È 08:23:31
²Ä 6573 ½g¦^À³
|
TREK-DX ¬O²Ä¤@Ó¦b¸g¾ú dupilumab ªº²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¸sÅ餤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¬ã¨s¡A¤w¶}©l®Ú¾Ú§ó·sªº¤è®×¦b¬ü°ê©Û¶Ò±wªÌ¡F ·sªº¼Ú¬w¯¸ÂI¹wp©ó 2024 ¦~¤W¥b¦~¶}·~ ¦b¹ï¨´¤µ¬°¤î±µ¨üªvÀøªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªºªì¨B¼f¬d¤¤¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22)ªº±wªÌ¹F¨ì¤F16 ¶g«á vIGA µû¤À¬° 0 ©Î 1¡]¥Ö½§³z©ú©Î´X¥G³z©ú¡^¡C ¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬ Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦VIL-13R »PIL-4R ªº®ÄªG¦s¦b®t²§¡Aªí©úeblasakimab ¦³¥i¯à¹ïDupilumab ¥¼¹F¨ì¨¬°÷¤ÏÀ³ªºAD ±wªÌ¦³®Ä¡A³o¬O¤@Ó«n¥BªA°È¤£¨¬ªº±wªÌ¸sÅé¡A«Ü¤Ö¦³¦w¥þ©Mªø´ÁªºªvÀø¿ï¶µ¡A
¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2024 ¦~3 ¤ë11 ¤é¡]Àô²y³q°TªÀ¡^¡XASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§J¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¡G¸Ó¤½¥q¤w¶}©l¦b¬ü°ê®Ú¾Ú¥¿¦b¶i¦æªºTREK-DX ¸ÕÅ窺§ó·s¤è®×©Û¶Ò±wªÌ¡A¦b¨Ï¥Î¹Ldupilumab ªº¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢(AD) ±wªÌ¤¤¬ã¨seblasakimab¡C
TREK-DX ¬O²Ä¤@Ó¦b¬J©¹±µ¨ü¹L dupilumab ªvÀøªº AD ±wªÌ¤¤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅç¡A¸Ó¥«³õ¹wp¨ì 20291 ¦~±N¹F¨ì 100 »õ¬ü¤¸¡C±j½Õ¤F¬ü°êAD ±wªÌ¸sÅ骺ÅܤơA TREK-DX ¯Ç¤J¼Ð·Ç¤w¦¬ºò¡A¥H©Û¶Ò°ò½uÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI) µû¤À¦Ü¤Ö¬°18¡]¦Ó¤£¬O16¡^ªº±wªÌ¡C»P¦¹¬Ûµ²¦X¡A¿W¥ßµû¼fû°ò½u EASI ¤À¼Æªº½T»{¤]¤w¹ê¬I¡C ¬ü°êªº¯¸ÂI¥Ø«e¥¿¦b®Ú¾Ú§ó·sªº¼Ð·Ç©Û¶Ò±wªÌ¡A¼Ú¬wªº¨ä¥L¯¸ÂI¹wp±N©ó 2024 ¦~¤W¥b¦~¶}©ñ¡C
TREK-DX ±N©Û¶Ò¬ù 75 ¦W¦]¥ô¦óì¦]¡]¥]¬A AD ±±¨î¤£¥R¤À¡BµLªk¶i¤J©Î¤£¨}¨Æ¥ó¡^°±¤î dupilumab ªvÀøªº±wªÌ¡A¨Ã¨C¶g¨Ï¥Î 400 ²@§J eblasakimab ©Î¦w¼¢¾¯ªvÀø¥LÌ¡A«ùÄò 16 ¶g¡C ¦b¹ï®Ú¾Úì©l¯Ç¤J¼Ð·Ç¤J²Õªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªì¨B¼f¬d®É¡A³o¨Ç±wªÌ«ö2:1 ªº¤ñ¨ÒÀH¾÷¤À¬°¬¡©ÊÃĪ«²Õ©M¦w¼¢¾¯²Õ¡A¦b¼Æ¾ÚºI¤î®É¡A17 ¦W±wªÌ§¹¦¨¤F16 ¶gªºªvÀø´Á¡A5 ¦W±wªÌ¦b§¹¦¨«e°±ÃÄ16¶gªºªvÀø´Á¡C ¦b²Ä16 ¶g©Î³Ì«á¤@¦¸´N¶E®É¡A10 ¦W±wªÌ¡]§Y45%¡^ªºEASI µû¤À¤U°¤F¦Ü¤Ö90%¡]EASI-90¡^¡A11 ¦W±wªÌ¡]§Y50%¡^¹F¨ì¤F0 ©Î1 ¤Àªº¸g¹LÅçÃÒªº¬ã¨sªÌ¾ãÅéµû¦ô(vIGA) µû¤À¡]³z©ú©Î´X¥G³z©úªº¥Ö½§¡^¡C ¦b¥ý«e¹ïdupilumab ¤ÏÀ³¤£¨¬ªº9 ¦W±wªÌ¤¤¡A5 ¦W±wªÌ(56%) ¹F¨ìEASI-90¡A5 ¦W±wªÌ(56%) vIGA µû¤À¬°0 ©Î1¡C¨´¤µ¬°¤î¡AªvÀø@¨ü©Ê¨}¦n¡A¨S¦³·sªº¦w¥þ©Ê°T¸¹³QÃѧO¡C ¥Ø«eÁÙ¨S¦³µ²½¤ª¢ªº³ø§i¡A¤]¨S¦³µù®g³¡¦ì¤ÏÀ³ªº³ø§i¡C ¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬¡C
¡u63% ±µ¨üdupilumab ªvÀøªº±wªÌ¦b16 ¶g«á¥¼¯à¹F¨ì³z©ú©Î´X¥G³z©úªº¥Ö½§¡]IGA µû¤À¬°0 ©Î1¡^2¡A¨Ã¥B¦b¹F¨ì³oºØ¤ÏÀ³ªº±wªÌ¤¤¡A¤j¬ù¤@¥b¦bÀH«áªº36 ¶g«á¨S¦³ºû«ù³oºØ¤ÏÀ³3¡A¦]¦¹¢¤Á»ÝnÃB¥~ªº¥Íª«Àøªk¡A¬°¹ï dupilumab ¨S¦³¨¬°÷¤ÏÀ³ªº±wªÌ´£¨Ñ¦w¥þ¦³®Äªºªø´ÁªvÀø¿ï¾Ü¡C EASI-90 ©M vIGA ¬O AD ¬ã¨s¤¤³ÌÄY®æªº²×ÂI¤§¤@¡C ¾¨ºÞ³o¬O°ò©ó¹ïª¼ªk¼Æ¾Úªºªì¨B¼f¬d¡A¦ý§Ú̹ªÀyÆ[¹î¨ì TREK-DX ¬ã¨s¤¤¨´¤µ¬°¤î¹F¨ì³o¨Ç²×ÂIªº±wªÌ¤ñ¨Ò«Ü°ª¡C §Ú̪º¥«³õ¬ã¨sµo²{¡A¤j¦h¼Æ AD ±wªÌ¹ï¥Ø«eªºªvÀø¶È·P¨ì¤¤µ¥º¡·N«×¡C ³o»P§Ú̲£¥ÍªºÂà¤Æ¼Æ¾Ú¤@°_¤ä«ù¤F eblasakimab §@¬°³o¨Ç±wªÌªvÀøªº¼ç¦b§@¥Î¡A¨Ã¥B§Ú̦b TREK-DX ¬ã¨s¤¤²£¥Íªº¼Æ¾Ú¥i¥HÃÒ©ú¡A¹ï©ó³\¦h±wªÌ¨Ó»¡¡Aeblasakimab ¬Æ¦Ü¥i¥H±±¨î¥L̪º¯e¯fdupilumab «o¨S¦³¡A ¡vASLAN »sÃĤ½¥q°õ¦æªøCarl Firth ³Õ¤h»¡¡C
Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦V IL-13R »P IL-4R ªº®ÄªG¦s¦b®t²§¡A³oªí©ú§Y¨Ï¦b dupilumab µL®Äªº±¡ªp¤U¡Aeblasakimab ¤]¦³¥i¯à¦³®Ä¡C Eblasakimab °w¹ï 2 «¬¨üÅ骺 IL-13 ¨üÅé (IL-13R) ¨È°ò¡Aªý¤î³z¹L¥Õ¦å²y¤¶¯À 4 (IL-4) ©M¥Õ¦å²y¤¶¯À 13 (IL-13) ªº°T¸¹¶Ç¾É¡C ¨âªÌ³£¬OAD µoª¢ªºÃöÁäÅX°Ê¦]¯À¡AµM¦Ó¡A³ÌªñµoªíªºÂà¤Æ¼Æ¾Ú±j½Õ¤F¦bAD ±wªÌ¥~©P¦å³æ®Ö²ÓM¤¤¡Aeblasakimab ¹v¦VIL-13R ¬Û¹ï©ódupilumab ¹v¼ÐIL-4 ¨üÅé(IL-4R)ªºÀu¶Õ4¡C »P IL-4R ªýÂ_¬Û¤ñ¡AIL-13R ªýÂ_¥i§ó¦³®Ä¦a´î¤Ö»P 2 «¬ÅX°Ê¡]¹L±Ó©Ê¡^µoª¢¦³Ãöªº²ÓM¦]¤l¡A¨Ã°§C 1 «¬«Pª¢²ÓM¦]¤lªº¤ô¥¡C ¨Ó¦Û AD ±wªÌ¥Ö½§¬¡Àˤ¤ eblasakimab ©M dupilumab ªºÀY¹ïÀY¬ã¨sªº¨ä¥L¼Æ¾ÚÃÒ¹ê¤F¹v¦V IL-13R »P IL-4R5 ªº®t²§¤Æ®ÄªG¡C ¦b³o¶µ¬ã¨s¤¤¡Aeblasakimab ¤ñ dupilumab §ó¦³®Ä¦a´î¤Ö¤F¥Ö½§²Õ´«Pª¢ 2 «¬²ÓM¦]¤lªº§½³¡¤Àªc¡A³oªí©ú eblasakimab ¥i¯à¹ï dupilumab ¥¼²£¥Í¨¬°÷¤ÏÀ³ªº AD ±wªÌ¦³®Ä¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/11 ¤U¤È 08:16:04
²Ä 6572 ½g¦^À³
|
TREK-DX ¬O²Ä¤@Ó¦b¸g¾ú dupilumab ªº²§¦ì©Ê¥Ö½§ª¢ (AD) ±wªÌ¸sÅ餤¶i¦æªºÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¬ã¨s¡A¤w¶}©l®Ú¾Ú§ó·sªº¤è®×¦b¬ü°ê©Û¶Ò±wªÌ¡F ·sªº¼Ú¬w¯¸ÂI¹wp©ó 2024 ¦~¤W¥b¦~¶}·~ ¦b¹ï¨´¤µ¬°¤î±µ¨üªvÀøªº22 ¦W±wªÌªºª¼ªk¼Æ¾Ú¶i¦æªºªì¨B¼f¬d¤¤¡A45% (10/22) ªº±wªÌªºEASI µû¤À(EASI-90) ¦Ü¤Ö°§C¤F90%¡A50% (11/22)ªº±wªÌ¹F¨ì¤F16 ¶g«á vIGA µû¤À¬° 0 ©Î 1¡]¥Ö½§³z©ú©Î´X¥G³z©ú¡^¡C ¹wp§¹¾ã¸ê®Æ¶°¤¤ªº«Dª¼¸ê®Æ±N©ó 2024 ¦~©³µo¥¬ Âà¤Æ¼Æ¾Úªí©ú¡A¹v¦VIL-13R »PIL-4R ªº®ÄªG¦s¦b®t²§¡Aªí©úeblasakimab ¦³¥i¯à¹ïDupilumab ¥¼¹F¨ì¨¬°÷¤ÏÀ³ªºAD ±wªÌ¦³®Ä¡A³o¬O¤@Ó«n¥BªA°È¤£¨¬ªº±wªÌ¸sÅé¡A«Ü¤Ö¦³¦w¥þ©Mªø´ÁªºªvÀø¿ï¶µ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/7 ¤U¤È 11:34:33
²Ä 6571 ½g¦^À³
|
¤½¥q¤T¤ë¤»¤é«n°T®§¡A¨â¦ì¬ì¾ÇÅU°Ý¾Ç¸g¾ú
2024 ¦~ 3 ¤ë 6 ¤é ªü´µÄõ»sÃĤ½¥q (ASLAN Pharmaceuticals) ¤½§G Eblasakimab ªvÀøºC©Êªý¶ë©ÊªÍ¯f (COPD) ªº·sÂà¤Æ¼Æ¾Ú¡A¨Ã¥ô©R»â¥ýªº©I§l¨t²Î±M®a¬°¬ì¾ÇÅU°Ý ¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¹ïeblasakimab©Mdupilumab¶i¦æªºÀY¹ïÀY¬ã¨sªº·sÂà¤Æ¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡Aeblasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è±Àu©ódupilumab »â¥ýªº©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h©M Reynold Panettieri Âå¾Ç³Õ¤h³Q¥ô©R¬°¬ì¾ÇÅU°Ý¡A¬°eblasakimabªº®t²§¤Æ¥H¤Î¥¼¨Ó COPDÁ{§É¶}µo´£¨Ñµ¦²¤«Øij ¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A 2024 ¦~ 3 ¤ë 6 ¤é¡V ASLAN Pharmaceuticals Ltd.¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤F¨Ó¦Û¤@®a¤½¥qªº·sªº¿n·¥Âà¤Æ¼Æ¾Ú¡C¦bºC©Êªý¶ë©ÊªÍ³¡¯e¯f (COPD) ¤HÅé²Õ´¼Ò«¬¤¤¹ïdupilumab»PeblasakimabCOPD¥Íª«Àøªkªº¼ç¤O´£¨Ñ¤F¶i¤@¨B¤ä«ù¡C¦¹¥~¡A¸Ó¤½¥qÁÙ«Å¥¬¥ô©R©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h¡B«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡BÂå¾Ç³Õ¤h¡Bù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø Reynold Panettieri Jr ³Õ¤h¬° ASLAN ¬ì¾Ç¹Î¶¤¦¨û¡C¿Ô¸ß©eû·|¥¿¦bµû¦ôeblasakimab§@¬°ªvÀøºC©Êªý¶ë©ÊªÍ¯f¥H¤Î²§¦ì©Ê¥Ö½§ª¢(AD) ªº¼ç¦bÀøªk¡C
¡u¦b»P ASLAN ¹Î¶¤¦X§@¡A±qeblasakimab©Mdupilumab¦b COPD ±wªÌ²Õ´¤¤ªºÀY¹ïÀY¬ã¨s¤¤Àò±o¥O¤H¦L¶H²`¨èªºÂà¤Æ¼Æ¾Ú«á¡A§Ú«Ü°ª¿³¥¿¦¡¥[¤J¬ì¾ÇÅU°Ý©eû·|¡A¶i¤@¨B±´¯Áeblasakimab¦b COPD ¤¤ªº¼ç¤O¡A¡¨³Õ¤h»¡
¡u§Ú«Ü°ª¿³¯à»P ASLAN ¹Î¶¤¦X§@¡A§Q¥Î³oÓ¥O¤H¿³¾Äªº¾÷·|¨Óµû¦ôeblasakimab¦b COPD¡]¤@ºØ 2 «¬ÅX°Ê¯e¯f¡^¤¤ªº¶}µo¸ô®|¡C§Ú¬Û«H¥Íª«»s¾¯¦³«Ü¤jªº¾÷·|§ïÅܳoºØºC©Ê¯fªºªvÀø®æ§½¡A´N¹³§Ú̦b¨ä¥L©I§l¨t²Î¯e¯f¦pÄY«®ð³ÝªºªvÀø¤¤©ÒÆ[¹î¨ìªº¡C³o¨Ç·s¼Æ¾Úªí©úeblasakimab¦³¼ç¤O¦¨¬° COPD ªº¤@¬y¥Íª«ÀøªkÃĪ«¡A§Ú´Á«Ý§Ú̪º¦X§@¹Ù¦ñÃö«Y¡A¡vù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø Reynold Panettieri Jr ³Õ¤h»¡¡C
2023 ¦~ 11 ¤ë¡AASLAN «Å¥¬¤F¨Ó¦Û°·±d®½Ãت̲Õ´ªºÂà¤Æ¼Æ¾Ú¡AÅã¥Üeblasakimab§@¬° COPD ªvÀøÃĪ«§í¨î 2 «¬µoª¢ªº¼ç¤O¡C¨Ï¥Î COPD ±wªÌªºªÍ²Õ´¶i¦æ¤F¶i¤@¨Bªº¬ã¨s¡A¤ñ¸û¤F¬Û¦P¿@«×ªºeblasakimab©Mdupilumab¡C¨CºØªvÀø±ø¥ó§¡¦b¦Ü¤Ö 6 Óºë½T¤Á³ÎªºªÍ¤Á¤ù¤¤¶i¦æ´ú¸Õ¡C¦b COPD ±wªÌ²Õ´¤¤¡Aeblasakimab¥i¦³®Ä«ì´_¦¬ÁY¡A¥HÀ³¹ï IL-4 ©M IL-13 ªº¬D¾Ô¡A¨Ã¦b¦¬ÁYªº®ð¹D¤¤ªí²{¥XºÖ²ö¯Sù»¤¾Éªº§Ö³t®ð¹DÂX±i¡CºÖ²ö¯Sù¬O¤@ºØªø®Ä£]¨üÅé¿E°Ê¾¯¡A¬O®ð³Ý©MºC©Êªý¶ë©ÊªÍ¯f±wªÌ±`¥Îªº¤@ÃþÃĪ«¡Cȱoª`·Nªº¬O¡Aªì¨B¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡A eblasakimab¦b¦hÓ»â°ìªºªí²{Àu©ódupilumab¡A¥]¬A IL-4 ©M IL-13 §ðÀ»«á®ð¹D¥\¯àªº«ì´_ ¡C
¡u§Ú̬۫Heblasakimab¦³¼ç¤O¦¨¬°»â¥ýªºªvÀø¿ï¾Ü¡A¦]¬°§ÚÌ¥¿¦b±´¯Á¨ä¦b AD ¥H¥~ªº¨ä¥L¯e¯f¤¤ªº¾A¥Î©Ê¡A¨Ò¦p COPD¡A³o¬O¤@Ó©|¥¼Àò±o§å㪺¥Íª«»s¾¯ªº¤j«¬¥«³õ¡C§ÚÌ´Á«Ý»P Krishnan ³Õ¤h©M Panettieri ³Õ¤h¥H¤Î¼ç¦b¦X§@¹Ù¦ñ¦X§@¡A¦Ò¼{ COPD ªº¼ç¦b·§©ÀÅçÃÒ²Ä 2 ´Á¬ã¨s³]p¡A¨Ã±´¯Á³Ìªñ¶i¦æªº¥Íª«¾Ç¬ã¨s¤¤ªº·s²×ÂI¡A¡vASLAN º®u°õ¦æ©x Carl Firth ³Õ¤h»¡
¦³ÃöeblasakimabªvÀøºC©Êªý¶ë©ÊªÍ¯fªº§ó¦hÂà¤Æ¼Æ¾Ú±N¦b§Y±N¥l¶}ªº¬ì¾Ç¤j·|¤W´£¥æµoªí¡C
Ãö©ó Ramaswamy Krishnan¡A«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡Bõ¾ÇºÓ¤h¡B³Õ¤h
Ramaswamy Krishnan³Õ¤h¬O«¢¦òÂå¾Ç°|«æ¶EÂå¾Ç°Æ±Ð±Â¡C¥Lªº¹êÅç«Ç±Mª`©óªÍ¤O¾Ç©M¾÷±ñ¶Ç¾É¡A±Mª`©ó®ð¹D¦p¦ó¦¬ÁY©M©ñÃP¡C¬°¦¹¡A¥Lµo©ú¤F¤@®M§Þ³N¨Ó´ú¶q®ð¹D²ÓM©M²Õ´ªº¦¬ÁY¡BÃP¦¢¡B¤O¶Ç»¼©M¤O¶Ç¾É¡C³o¨Ç§Þ³N¤£¶È¨Ï¥L¦Û¤vªº¹êÅç«Ç¯à°÷µo²{ªvÀøºC©Êªý¶ë©ÊªÍ¯f©M®ð³Ýªº·sÔ¿ïÃĪ«¡A¦Ó¥BÁÙ¦b¥þ²y½d³ò¤º³Q¥Î§@µû¦ô«Ý©wÔ¿ïÃĪ«ªº¤ä®ðºÞ«OÅ@©M¤ä®ðºÞÂX±i¥\¯àªºÂà¤Æ¤èªk¡CKrishnan ³Õ¤h¦bôÛ¤ñ¨È¤j¾ÇÀò±o¾÷±ñ¤uµ{³Õ¤h¾Ç¦ì¡A¨Ã¦b«¢¦ò¤j¾Ç¶i¦æªÍ¥Í²z¾Ç³Õ¤h«á¬ã¨s¡C¥Lµoªí¤F¶W¹L 75 ½g¤å³¹¡Bµû½×¡BªÀ½×©M³¹¸`¡A¨ä¤¤³\¦hµoªí¦b¡m¦ÛµM²ÓM¥Íª«¾Ç¡n©M¡m¦ÛµM§÷®Æ¡nµ¥µÛ¦W¦P¦æµû¼f´Á¥Z¤W¡C
Ãö©ó Reynold Panettieri Jr ³Õ¤h¡]Âå¾Ç³Õ¤h¡^ ù®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø
Reynold A Panettieri Jr Âå¾Ç³Õ¤h¬Où®æ´µ¤j¾ÇÂà¤ÆÂå¾Ç»P¬ì¾Ç¬ã¨s©Òªºº¥ô©Òªø©MÂà¤ÆÂå¾Ç»P¬ì¾Ç°Æ®Õªø¡A¦¹«e´¿¾á¥ô»«¦{¤j¾Ç®ð¹D¥Íª«¾Çp¹º¥D¥ô¡CPanettieri ³Õ¤hªº¹êÅç«Ç±Mª`©ó®ð¹D¥·Æ¦Ùªº§K¬Ì¥Íª«¾Ç¡BÀô¹Ò¬r¯À¹ï®ð¹D°ª¤ÏÀ³©Êªº¼vÅT¥H¤Î®ð³Ý©MºC©Êªý¶ë©ÊªÍ¯fªvÀø¤èªkªº·s¼Ð¹v©M¥¥xªºÃѧO¡C°£¤F¥Lªº¬ã¨s©MÁ{§É¿³½ì¤§¥~¡APanettieri ³Õ¤hÁÙ¾á¥ô NIH ªÍ²ÓM¡B¤À¤l©M§K¬Ì¥Íª«¾Ç¬ã¨s³¡ªùªº¥D®u¡A¨Ã¥B¬O NIH ³Ç¥X½s¿è¤p²Õªº¦¨û¡CPanettieri ³Õ¤hµoªí¤F¬ù 450 ½g¥Xª©ª«¡A¨Ã¦b»«¦{¤j¾Ç±µ¨ü¤FÂå¾Ç°ö°V¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/7 ¤U¤È 10:28:28
²Ä 6570 ½g¦^À³
|
A ¤j®a§Ñ¤F¶}µo¤@ºØÃĪ«¥i¥H¦³«Ü¦h¾AÀ³¯g ( eblasakimab ¶}µo²§¦ì©Ê¥Ö½§ª¢AD , ®ð³Ý»PºC©Êªý¶ë©ÊªÍ¯f COPD , Farudodstat ¶}µo Alopecia areata ¯ë¨r )
B Dupilumab experienced(½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w) ¤j®a·Q¤@·Q TREX-DX ¹êÅç¼Æ¾Ú¬OÀø®Ä¤ñ¸û«n ÁÙ¬O¦¤@ÂI¤½§i¼Æ¾Ú¤ñ¸û«n ? ¤½¥q½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡¬O¥¿½Tªº¿ï¾Ü
C Eblasakimab¬O¤@ºØ·s«¬¥þ¤H·½³æ®è IgG4 §ÜÅé¡A¥i¯S²§©Êµ²¦X¥Õ¦å²y¤¶¯À (IL)-13 ¨üÅé (IL-13R)¡A ªý¤î³z¹L 2 «¬¨üÅé¶Ç»¼ IL-4 ©M IL-13 °T¸¹¡C 2 «¬¨üÅé¬O¥]§tIL-4¨üÅé(IL-4R)©MIL-13¨üÅé(IL-13R) ªº²§¤G»EÅé¡C²ÓM¿E¯À IL-4 ©M IL-13 ³z¹L 2 «¬¨üÅéµo¥X°T¸¹¡A¬Oµoª¢ªºÃöÁäÅX°Ê¦]¯À¡A¬O¤Þµo AD¡B®ð³Ý ©M COPD µ¥ 2 «¬¯e¯fªº¹L±Ó¯gª¬ªºÃöÁä
D 2024 ¦~ 3 ¤ë 6 ¤éªü´µÄõ»sÃĤ½¥q (ASLAN Pharmaceuticals) ¤½§G Eblasakimab ªvÀøºC©Êªý¶ë©ÊªÍ¯f (COPD) ªº·sÂà¤Æ¼Æ¾Ú¡A¦b COPD ¤HÅé²Õ´¼Ò«¬¤¤¹ïeblasakimab©Mdupilumab¶i¦æªºÀY¹ïÀY¬ã¨sªº·sÂà¤Æ ¼Æ¾ÚÅã¥Ü¡A¦b¬Û¦P¿@«×¤U¡Aeblasakimab¦b§ïµ½®ð¹D¥\¯à©M¼W±j¤ä®ðºÞÂX±i¤è±Àu©ódupilumab
E »â¥ýªº©I§l¨t²Î±M®a Ramaswamy Krishnan ³Õ¤h©M Reynold Panettieri Âå¾Ç³Õ¤h³Q¥ô©R¬°¬ì¾ÇÅU°Ý¡A¬°eblasakimabªº®t²§¤Æ¥H¤Î¥¼¨Ó COPDÁ{§É¶}µo´£¨Ñµ¦²¤«Øij (¹ï¤S¤@Ӧʻõ¬ü¤¸ªº¾AÀ³¯g °Ê§@¶W§Ö¬O¥i²z¸Ñªº)
Dupilumab¤]¬O¤@¼Ë¶}µo«Ü¦h¾AÀ³¯g Dupilumab¾A¥Î©óªvÀø¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ª¢(2017 FDA )¡B¤¤«×¦Ü««×®ð³Ý(2018 FDA) ¡A ¥H¤ÎªvÀø¦ñÀH»ó®§¦×ªººC©Ê»óÄuª¢
2022 ¦~ 5 ¤ë¡Adupilumab ªº·s¾AÀ³¯gªvÀø12 ·³¤Î¥H¤W¡BÅé«¦Ü¤Ö 40 ¤½¤ç¡]88 ½S¡^ªº¤Hªº ¶Ý»Ä©Ê²É²ÓM©Ê¹¹Dª¢
2022 ¦~ 9 ¤ë¡Adupilumab ªº·s¾AÀ³¯g¬°¥]¬AªvÀø¦¨¤Hµ²¸`©ÊÄo¯l¡]PN¡^
¬ã¨s¤¤ COPD 2023 ¦~ 3 ¤ë¡AÁɿյ᤽§G¤F¤@¶µ 3 ´Á¸ÕÅ窺µ²ªG¡A¸Ó¸ÕÅçÀˬd dupilumab ªvÀø ºC©Êªý¶ë©ÊªÍ¯f(COPD) ªºÀø®Ä¡C¦b³o¶µÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¸ÕÅ礤¡Adupilumab ÃÒ©ú COPD ¤¤«×©Î««×«æ©Ê´c¤Æ´î¤Ö 30%¡A¥B COPD ±wªÌªºªÍ¥\¯à©M¥Í¬¡«~½èÅãµÛ§ïµ½
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/3/7 ¤U¤È 12:28:16
²Ä 6569 ½g¦^À³
|
§Úı±oÀ³¬OTREX-DX¸ÕÅç¼Æ¾Ú¤£¦n¡A
©Ò¥H¤~Åܧ󦬮׹ï¶H¤§¼Ð·Ç¡A
²{ªp¤S¨S¸g¶O°µ004 3´Á¸ÕÅç¡A
¥ý§äÓ±µÄò´À¥NpµeÄ~Äò©¿巄¤j®a¡A ¬Ý¯à¤£¯à¦bÄFÂI¸g¶Oª¯©µ´Ý³Ý¡A
¤£ºÞ¬O¨rÀYÃĩάOCOPDÃÄ¡A
³£¬Oªü¤TÄF¿ú¥Îªº¤â¬q¡A µL¸Û«Hªº¤½¥q¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2024/3/7 ¤W¤È 08:56:36
²Ä 6568 ½g¦^À³
|
«æº¦¤Å³ß¡A«æ¶^¤Å¼~¡F±o¤§§Ú©¯¡A¥¢¤§§Ú©R¡F¬Ýºò²ü¥]¡A¬ÕÁ«¦Ût! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/3/6 ¤U¤È 10:38:33
²Ä 6567 ½g¦^À³
|
3h«eªº·s»D
¤§«e°µ¥Ö½§¹L±Ó ²{¦b§ïÅÜ·s¤è¦V¥h°µ©I§l¹DªÍ¯f?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/3/1 ¤U¤È 10:32:44
²Ä 6566 ½g¦^À³
|
¤½¥qªº¬ãµo²£«~¥Dn¥H¤jÃĬ°¥D ¨âÁû¤jÃÄ©è¹L¤QÁû¤pÃÄ
§Ú̪º²£«~²Õ¦X¥H eblasakimab ¬°¥D¾É¡A³o¬O°w¹ï IL-13 ¨üÅ骺¼ç¦b¤@¬y§ÜÅé¡A¦³¥i¯à §ï¶i¥Ø«e¥Î©óªvÀø¹L±Ó©Ê¯e¯fªº¥Íª«»s¾¯¡C §Ṳ́]¥¿¦b¶}µo Farudodstat¡A¤@ºØ DHODH 酶 ªº¦³®Ä¤fªA§í¨î¾¯¡A§@¬°ªvÀø´³¨rªº¼ç¦b¤@¬yÀøªk¡C
1 Eblasakimab IL-13R£\1 Atopic dermatitis ¬O¤@ºØ¥¿¦b¶}µoªº¥Î©ó¤¤««× AD ªº·s«¬¥Íª«»s¾¯¡A¦³¥i¯à±q¤@¶}©l´N´£¨Ñ¨C¤ë¤@¦¸ªºµ¹ÃĤè®×¡A¥B¤£¼vÅTÀø®Ä
¨Ì¾Ú¤½¥q2024¦~¤@¤ë²³ø ¨ì2029¦~ ²§¦ì©Ê¥Ö½§ª¢¥þ²y¥«³õ190»õ¬ü¤¸ 2 Dupilumab experienced ½Õ¾ã¦¬®×µ¦²¤ ¥H®É¶¡´«¨ú§ó¨ÎÀø®ÄªºªÅ¶¡ (¨Ï¥ÎDupilumab®ÄªG¤í¨Îªº¯f±w)
T 3 Type 2-driven disease (¤G«¬ª¢¯g) 81% ²§¦ì©Ê¥Ö½§ª¢¯f±w¦³¤G«¬¬ÛÃöª¢¯g( ¦p¹L±Ó ®ð³Ý)
4 ¨ä¥L¦³¼ç¤O¾AÀ³¯g COPD ºC©Êªý¶ë©ÊªÍ¯f 5 Farudodstat DHODH Alopecia areata Phase 2a interim topline data mid-2024 2022 ¦~¬ü°ê´³¨r¡]²æ¾v¡^ªvÀø¥«³õ¦ôȬ° 34.44 »õ¬ü¤¸¡A¹wp 2023 ¦~¦Ü 2030 ¦~½Æ¦X¦~¼W ªø²v¬° 5.50%¡A¨ì 2030 ¦~¹F¨ì 52.85 »õ¬ü¤¸¡C(¥þ²y¥«³õ2030¦~ 137»õ¬ü¤¸) ¨Ì¾Ú¤½¥q2024¦~¤@¤ë²³ø´³¨r²×¥Íµo¯f²v¦Ê¤À¤§2.1% 2020¦~¬ü°ê¯f±w70¸U¤H ¨ä¤¤¦Ê¤À¤§25 ÄÝ©óÄY«±¡ªp 62%´³¨r¯f±w·|±µ¨üÃĪ«ªvÀø
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/3/1 ¤W¤È 01:56:33
²Ä 6565 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/29 ¤U¤È 10:23:10
²Ä 6564 ½g¦^À³
|
2024 ¦~ 2 ¤ë 29 ¤é ªü´µÄõ»sÃĤ½¥q Farudodstat ªºª«½è²Õ¦Xª«±M§Q¥Ó½Ð¼Ú¬w±M§Q§½ªº¦nµû farudodstatªº·sª«½è²Õ¦X±M§Q±N¥[±j´¼¼z°]²£Åv«OÅ@¡A¨Ã¬°farudodstat´£¨Ñ°Ó·~¿W¦ûÅv¡A ¦Ü¤Ö«ùÄò¨ì 2043 ¦~¥[¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2024 ¦~ 2 ¤ë 29 ¤é¡V ASLAN Pharmaceuticals Ltd. ¬O¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¨ä ¤wÀò±o¦³§Qªº±M§QÅv§@¬°°ê»Ú¼f¬dûªº¼Ú¬w±M§Q§½ (EPO) ¹ïFarudodstatªº¦h´¹«¬±M§Q¥Ó½Ðµoªí¤F·N¨£¡A ¦pªG¦b°ê®a¶¥¬qÀò±o§åã¡A±N§âFarudodstatªº¦³®Ä±M§Q«OÅ@©µªø¦Ü¦Ü¤Ö 2043 ¦~¡C
Farudodstat¬O¤@ºØ¦³®Äªº¤fªA¤G²B¨Å²M»Ä²æ²B酶 (DHODH) §í¨î¾¯¡A¦³¥i¯à¦¨¬°´³¨r (AA) ªº¤@¬yªvÀø ¿ï¾Ü¡CASLAN ¥Ø«e¥¿¦b AA ¤¤¶i¦æ 2a ´Á·§©ÀÅçÃÒ¸ÕÅç¡]¡uFAST-AA ¬ã¨s¡v¡^¡A¹wp¸Ó¬ã¨sªº¤¤´Áµ²ªG ±N©ó 2024 ¦~¤¤´Á¤½§G¡C
ASLAN Pharmaceuticals °õ¦æªø Carl Firth ³Õ¤h»¡¡C ¡u§ÚÌ«Ü°ª¿³¦¬¨ì¼Ú¬w±M§Q§½Ãö©ófarudodstatª«½è²Õ¦¨±M§Q¥Ó½Ðªº¥¿±ªì¨B·N¨£¡A¨Ã»{¥i§ÚÌ©Ò¦³ ªºÅv§Qn¨D§¡¨ã¦³·s¿o©Ê©M³Ð³y©Ê¡C¦pªG¦b°ê®a¶¥¬qÀò±o±ÂÅv¡A·s±M§Q±N§âfarudodstatªº±M§Q«OÅ@ ©µªø¦Ü¦Ü¤Ö2043¦~¡C³o±NÅãµÛ¼W±jfarudodstatªº°Ó·~¿W¦û©Ê¡A¬O§Ú̦b©Ò¦³ÃöÁä°Ó·~»â°ìfarudodstat ¥[±j ¥Ñ©ó´³¨r±wªÌ¥i¥ÎªºªvÀø¿ï¾Ü«Ü¤Ö¡A§Ú̪º¥Ø¼Ð¬O¬°±wªÌ´£¨Ñ¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C
Ãö©ó Farudodstat
Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í¨î¾¯¡A¥i³z¹LªýÂ_ DNA ½Æ»s©Ò»ÝªºáGÔr±qÀY ²£¥Í¨Ó §í¨î§K¬Ì²ÓM¼W´Þ©M IFN-£^ ¤Àªc¡C»P²Ä¤@¥N DHODH §í¨î¾¯¬Û¤ñ¡A farudodstat ¹ï DHODH ©M T ²ÓM¬¡©Êªº§í¨î®ÄªG¬ù¬° 30 ¿¡A¨Ã¥B¨ã¦³¨}¦nªº@¨ü©Ê¦w¥þ©Ê¡CASLAN ²£¥Íªº¼Æ¾ÚÅã¥Ü¡A farudodstat ¥i¥H¼ç¦b¦a¨¾¤î¤òÅn§K¬Ì¯SÅv³à¥¢¡A¤ä«ù¨ä§@¬° AA ¤@¬yªvÀø¿ï¾Üªº¼ç¤O¡C AA ªº 2a ´Á·§©ÀÅçÃÒ¸ÕÅç¡]FAST-AA ¬ã¨s¡^¥Ø«e¥¿¦b¶i¦æ¤¤¡A¹wp±N©ó 2024 ¦~¤¤´Á¤½§G¤¤´Áµ²ªG¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/27 ¤U¤È 09:20:32
²Ä 6563 ½g¦^À³
|
NVIDIA(½÷¹F) 22¤é¤½¥¬°]³ø¡Aªí²{¶W¥G·Q¹³ªº¦n¡A¬Q¤éªÑ»ù790.92 USD ¡I ¯¸¦bAI®ö¼é¦yºÝªº¥L¡A¶À¤¯¾±ªñ¤é«o¶}¥Ü¥Í©R¬ì¾Ç¤~¬O¥¼¨ÓÅã¾Ç |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/2/27 ¤U¤È 06:36:11
²Ä 6562 ½g¦^À³
|
1.§ÚÁöµM¤£¬Ý¦nASLAN¡A¦ý¤]¤£±Æ°£³Ì«áµ²ªG¥´Áy§Ú¡A¤£¹L¦³¤@説¤@¡A°ò¥»¤W13F¤£¥i¯à´¦ÅS«ù¦³³¡¦ìªº¶R¶i»ù®æ¡A´N¹³¤Úµá¯S¤§«e¶R¶i¥x¿n¹q¡A¤j®a¤]¥u¯àÂÇ¥Ñ13F¥h§PÂ_¶R¶iªº®É¶¡ÂI¬O²Ä´X©u¶i¦Ó¥h¦ôºâ§¡»ù¡Awhalewisdom.com¤W±ªº»ù®æ¤]¥u¬O°Ñ¦Ò¡Awhalewisdom.com¨Ã¤£·|³qÆF¡A©Ò¥H§Ú¤~»¡ºô¯¸¸ê®Æ¦³À°¦£¾ã²z«ùªÑ¸ê®Æ½T¹ê¤è«K¡A¦ý¦³¨Ç¸ê°T°Ñ¦Ò§Y¥i¡A¤£¥Î¹L«×Ár´ú¡A»{¯un¬ÝÁÙ¬O¥h¬ÝSECªºì©l¸ê®Æ¤ñ¸û¦n¡C 2.¸Û¦p¸Ø±i¤j©Ò»¡¡AASLAN¨Ã¤£¬O¼öªùªÑ²¼¡A©Ò¥H³o1.2¤¸«ç»ò¦ô¥X¨Óªº§Ú¤£ª¾¹D¡A¦ý«Ü©úÅãwhalewisdomªººô¯¸¸ê®Æ´N¬O2023Q4²Ä¤@¦¸¶R¶iªº«ùªÑ³£¬O1.2¤¸¡A¥h¥J²Ó¬Ý´NÆZ©úÅ㪺¡A¨Ò¦pBVF,Parkman Healthcare,Rhumbline³£¬O2023Q2²Ä¤@¦¸¶R¶i¡A¶R¶i»ù®æ¤]³£¬O3.65¡ASchonfieldÁöµM¬O3.24¡A¦ý¬O¬O¦]¬°«áÄò¦³¼W«ù¼vÅT¨ìwhalewisdomªº¦¨¥»pºâ¡A©Ô¦^¥hwhalewisdom¸ÌASLANªº2023Q2«ùªÑ¸ê®Æ¡A¥i¥H¬Ý¨ìSchonfied¶R¶i»ù®æ¤]¬O3.65¡A©Ò¥H¨ä¹ê¤£¦s¦b©Ò¿×¤º½uªº°ÝÃD°Õ¡A³»¦h´N¬O¦³7®a§ë¸ê¾÷ºc¶i¨Ó¦Ó¤w¡A¨ä¤¤¦³UBS³o¤j©@¡A´N¥u¬O³o»ò²³æ¡A¦pªG¯uªº¦³¤º½u¡AASLAN¥«È¤~¦h¤Ö¡Aª½±µ¶R¤U¨Ó³£¥i¥H¤F¡A7®a¦Xp¤~¶R¤J¤£¨ì150¸UªÑ¡A¥H0.5¤¸¨Óºâ¤]¤~75¸U¬ü¡A¸òªk¤Hªº§ë¸ê³¡¦ì¤ñ°_¨Ó¡A´N¬OªáÂI¤p¿ú¶RÓ¼Ö³z¦Ó¤w..... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/26 ¤U¤È 05:04:26
²Ä 6561 ½g¦^À³
|
¯u§Æ±æ¸Ø±i¤j©Ò¼gªº ¬O ¯«µo²{
¨È·à³oÓ»ù ½æ¤F ½ßÓª¯¦Y«Ë£½
¥u¯à§Ñ¤F¥¦ ¬ß°]¯«·Ý²²ÅU
ÁÂÁ¸رi¤j¡I¡I¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/26 ¤W¤È 08:40:51
²Ä 6560 ½g¦^À³
|
whalewisdom.com/stock/asln ¥h¦~²Ä¤T©uºI¤î¡A¦³22®a§ë¸ê¾÷ºc«ù¦³¨È·à±dªºªÑ²¼ ¦Ó¦Ü112/12/31(112¦~²Ä¥|©u)µ²§ô §ï¥Ñ23®a§ë¸ê¾÷ºc«ù¦³¨È·à±dªºªÑ²¼(6®a¥X²M¡B7®a·s¶i) (23®aºâ«Ü¤Ö¤F) ¦Ó23®aùر¦³7®a¬O¥h¦~²Ä¥|©u¤~è·s¶iªº§ë¸ê¾÷ºc 7®a¾÷ºc¦p¤U
1. UBS GROUP AG¶R¶i625,000ªÑ 2. SHAY CAPITAL LLC¶R¶i400,000ªÑ 3. LANDSCAPE CAPITAL MANAGEMENT, L.L.C.¶R¶i83,259ªÑ 4. XTX TOPCO LTD¶R¶i27,666ªÑ 5. JANE STREET GROUP, LLC¶R¶i23,093ªÑ 6. ONYX BRIDGE WEALTH GROUP LLC¶R¶i22,727ªÑ 7. CUTLER GROUP LLC¶R¶i1,000ªÑ
·s¶iªº7®a¥þ³¡³£¬O²Ä¤@¦¸¶R¶i¡A¤]³£¦P¤@»ù¦ì¡A¶R¶iªº»ù¦ì³£¬O1.2¤¸/ªÑ¡A³o»ò¥© (¦³¤º½u¤~´±¶i¨Ó¶R§a) ¥h¦~²Ä¥|©uªÑ»ù°ªÂI1.92¤¸¡AªÑ»ù§CÂI0.392¤¸ ½Ð¤j¤jÀ°¦£ºâ¤@¤U7®a³£¶R¦P¤@»ù¦ìªº¾÷²v¬O¦h¤Ö? (Y¤À§å¶R¡A³Ì«á¥§¡¬O1.2¤¸¤]¤£Â²³æ~~~¦ý½Ð¤£n³o»ò·Q) ¨È·à±d¤£¬O¼öªùªÑ§a(¼öªùªÑ(¥x¿n¹q-ADR)§Ú´N¬Û«H¬O¥©¦X)(´N¥ý¥H¤º½u¸ÑŪ)
¨ä¤¤112¦~Q4ªº·ç»È§Q¥ÎªÑªF¨¤À©ó113¦~1¤ë ¶i¦æ¡G 1.¸ò¨È·à±d°ª¼h°Q½×´M§ä¦X§@¹Ù¦ñ¶i«× 2.§ä¨ìªÑ²¼½æ®a(½æ®a¬°¦ón½æ?) 3.½Í¦n¥æ©ö»ù¦ì «á 113/2/6¦A¥[½X¥Ó³ø¶R¶i16,292,600ªÑ
ÁÙ¦³2/1~2/13ªº½L¤¤¨C¤ÀÄÁ¥æ©ö¤Î2/15¨C¤Q¤ÀÄÁ¥æ©ö1000ªÑªº¸ê°T¡A³£n¨ì5/15¤~ª¾¹D¡C³oÓ¤~¼F®`¡C (Y¨È·à±d5/15«e³Q¨Ö¡A§A´Nª¾¹Dþ¨Ç¤½¥q¦³¤º½u¤F)
¸ò¦U¦ì¤À¨É ¨Ã½Ð«ü¥¿(7®a³£¶R¦P¤@»ù¦ì¡A¦U¦ì¤j¤j¬Û«H¬O¥©¦Xªº½Ð»¡©ú¤@¤U¡A§ÚÅ¥¬Ý¬Ý¦X¤£¦XÅÞ¿è¡AÁÂÁÂ)(§ë¸ê·ÀI½Ð¦Û¦æµû¦ô)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/2/24 ¤U¤È 10:22:29
²Ä 6559 ½g¦^À³
|
1.Dupilumab¾P°âÃB°ª¡A°£¤FAD¥~¡A³o´X¦~«ùÄò§ð§J¤F¦h¶µ¾AÀ³¯g¸ò¥i¨Ï¥Î±Ú¸s¡ACOPD¤]¬OFDAª½±µµ¹Àu¥ý¼f¬dÅv¥[³t¼f®Ö³q¹L¡A¦³³o¨Ç¤~³y´N¤F¦Ê»õ¤jÃÄ¡AEblasakimab¤G´Á¤w¸g¹L¤F¤j¥b¦~¡A¹ï¤@Ó«ùÄò¿N¿úªº·sÃĤ½¥q¨Ó»¡¡A³o®ö¶Oªº®É¶¡¦¨¥»¥N»ù«D±`°ª©ù¡A¦pªGEblasakimab¯uªº¥«³õ¼ç¤O¦p¦¹Àu¨q¡A«ç·|©ì¤F³o»ò¤[ÁÙ¥d¦b³o¸Ì¡H¤@°ï¤jÃļt¦£µÛ©ï»ù¦X§@³£¨Ó¤£¤Î¤F¡A²{¦b´Nºâ¦³¦X§@¹ï¶H¥i¥H¿ï¾Ü¡A¤j·§²v³£¬O¦X§@±ø¥ó¤£¬Æ²z·Q¡A¤~·|¥d³o»ò¤[¡A²¦³º³o¤j¥b¦~´X¥G¬ãµo¨SÔ£¶i®i¡A¯uªº¦³¤jÃļt·P¿³½ìªº¸Ü¡AÀ³¸Ó¤G´Á«e´N¶}©l³W¹º¬¢½Í¡A¤G´Áµ²ªG¥X¨Ó´N«æµÛ±ÂÅv©Î¨ÖÁʤF¡AµoÓ¤G´Á¸ÕÅ窺¶i¤@¨B¥Íª«¼Ð°O¸ò¦¸±Ú¸s¤ÀªR´N§O»¡¬OÔ£¶i®i¤F¡A´N¬O¨S¿ú°µ¤T´Á¡A¥u¯à²`¤J¤ÀªR¤@¤U¤G´Á¼Æ¾Ú¡A¤£µMÁÙ¯à«ç»ò¿ì¡HCOPD¤]¥u¬O¤Á¤ù¹êÅç¡A³£ÁÙ¦bªì´Á±´¯Á´N¤£n¦n°ªÄE»·¤F¡A¥ý·Q¿ìªk±À¶iAD¤T´Á§a.... 2.whalewisdom.comªº¸ê®Æ§Ú¬O»{¬°°Ñ¦Ò§Y¥i¡A¦pªGn»{¯u¬ã¨s¬üªÑ¡AÁÙ¬O¥h¬Ý¤½¥qªºSEC¸ê®Æ¤ñ¸û·Ç½T¡A¥u³æ¾aºô¯¸¾ã²zªº¸ê®Æ¨ä¹ê¦³·ÀI¡A¦]¬°¸Ì±ªº¸ê®Æ¨ä¹ê¦³¨Ç¸Óµù©ú¨Sµù©úªº¡A¨Ò¦p¦³¨ÇªÑªFªº«ùªÑ³æ¦ì¬O¥ÎADS¡]25ªÑì©lªÑ¡^¡A¦³¨ÇªÑªFªº«ùªÑ³æ¦ì¬O¥Îì©lªÑ¡ABVF.K2³æ¦ì³£¬Oì©lªÑ¡AÀ³¸Ó¬O¦]¬°2023¦~¨p¶Ò¸ò»{ªÑÅvªº³æ¦ì³£¬Oì©lªÑªº½t¬G¡A©Ò¥HSEC¤å¥ó¤W¥Ó³øªº³æ¦ì¤]³£¬Oì©lªÑ¡Awhalewisdom.com¶È¶È¥u¬O§â¼Æ¦r¦C¤W¥h¦Ó¤w¡ABVF¹ê»Ú¤W«ùªÑ¼W¥[¡A¨Ã«D¬O±q¥«³õ¤W¶R¶i¡A¬O¥Ñ¤§«e¨p¶Ò»{ªÑÅv»{ªÑ¦Ó¨Ó¡A³o¦bSEC¤å¥ó¤¤³£¦³µù©ú¡A¦Ówhalewisdom.com¤W¨Ã¤£·|´¦ÅS¨ì³o»ò¸Ô²Ó¡C 3.¥H§ë¸ê¨Ó»¡¡AªÑ»ù²×¨s·|¦^Âk°ò¥»±¡A±q2018¦~ADS¾ú¥v³Ì°ª»ù52.195¨ì2024¦~ªÑ»ù¤£¨ì0.5¡A§O¦Aè¤ß¦k·Q¬O¥«³õ¨Sµo²{ASLANªº»ùȤF¡A¦Ó¬OASLAN¹ê»Ú¤W´N¥uȳo¼Ë¡A´L«¥«³õok? 4.½Ð¦Ñ·à¤Í̦ò¨t¬Ý«Ý«ùªÑ¡A¨S½ß´NºâÁȨì¤F¡A§O«ü±æ·|¤jÁÈ¡A²¦³º«ù¦³¦¨¥»À³¸Ó³£¤£§C¡A¤]§O·Q¤p¿ú¤jÅu¥¡A¨S¥²n¬°¤F¥W³æ·d¨ì³s¤p¿ú³£½ß¶i¥h¡A¤ñ°_¯{¿ú¦bASLAN¡A®³¥h§ë§Oªº¤ñ¸û¹ê»Ú........ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/24 ¤U¤È 05:48:12
²Ä 6558 ½g¦^À³
|
µ¥¸ó±i¤jªº
¾÷ºc«ùªÑ ¦³¦ó¥©¦X¤§¨Æ
ÁÂÁ±z¡I¡I¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/2/23 ¤W¤È 09:42:52
²Ä 6557 ½g¦^À³
|
³o³¾Âû¦ØªÑ¡A
©ñ±ó§a¡A
©{¦p¶BÄF¶°¹Î¡A
³s¤@ª½¹ª§jªº¤H¡A ¤]»{©R°h¥X¤£¨£¤F¡A
©ú¤Ñ¹L«á¤j¡A¤~¬O¥ýª¾¡A |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N10151329 |
µoªí®É¶¡:2024/2/23 ¤W¤È 09:35:26
²Ä 6556 ½g¦^À³
|
ÁÙ¥H¬°¤µ¦~·|ºCºC¤W¥h, µ²ªG¤S³oºØ¶^ªk ¤Ó§é¿i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/23 ¤W¤È 05:29:52
²Ä 6555 ½g¦^À³
|
¶ã©I«s«v¡I¡I¡I ªÑ»ù¤£µ¹¤O
³oºØ¶^ªk ¤Ó§é¿i¤H¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/17 ¤U¤È 10:57:15
²Ä 6554 ½g¦^À³
|
¥h¦~²Ä¥|©u,¾÷ºc«ùªÑÁÙ¦³§ó¥©ªº¨Æ,¤U¶g¤À¾å. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/17 ¤U¤È 09:51:47
²Ä 6553 ½g¦^À³
|
·ç»È·s¼W«ùªÑ¨Ó¨ì16,917,600ªÑ ( ¸ê°T¦b Page2 ) whalewisdom.com/stock/asln ·ç»È¦X¨Ö·ç«H«áÅD¤É¥þ²y²Ä¤G¤j°]´IºÞ²z¾÷ºc ¼W¥[ ASLN «ùªÑ ¥²¦³¨ä±M·~§PÂ_ªº²z¥Ñ
112/12/31¤î «ùªÑ²Ä1¦WBVF ì«ùªÑ8,488,000 ªÑ ·s¼W«ùªÑ34,856,975ªÑ Á`p43,344,975ªÑ «ùªÑ²Ä2¦WK2 ì«ùªÑ5,293,226 ªÑ ·s¼W«ùªÑ17,174,449ªÑ Á`p22,467,675ªÑ «ùªÑ²Ä3¦W·ç»È ì«ùªÑ625,000 ªÑ ·s¼W«ùªÑ16,292,000ªÑ Á`p16,917,600ªÑ
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis ¨ü¸Õ¨Ó¦Û¤£¦P°ê®a ¤£¦P¸~±Ú( ¬ü°ê ¥[®³¤j ¯Ã¦èÄõ ¿D¦{ ¦L«× ·s¥[©Y ªiÄõ) ( ¬ü¦{ ¿D¦{ ¨È¦{ ¼Ú¦{ )
CNTBªºCBP-201 ¤G´ÁÁ{§É ¬d¸ß ClinicalTrials.gov ¨ü¸Õ§½¦b¦Û¤v°ê®a ¦P¤@ºØ±Ú
®æ§½¤£¦P ¥ø¹Ï¤ß¤£¦P Àø®Ä»P¦w¥þ©Ê¤£¦P ¥@¬É¯Å¤jªÑªF«ùªÑ¤£¦P ---- »ùÈ·íµM¤£¦P
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/17 ¤U¤È 05:04:41
²Ä 6552 ½g¦^À³
|
¦³¾÷ºc½æ¥X¡A·íµM´N¦³¾÷ºc¶R¤J¡C (¦ý´N¬O³o»ò¥©¦X) ºI¦Ü112/12/31´N¦³6®a¾÷ºc¶R¦b¦P¤@»ù¦ì
1. UBS GROUP AG¶R¶i625,000ªÑ 2. SHAY CAPITAL LLC¶R¶i400,000ªÑ 3. LANDSCAPE CAPITAL MANAGEMENT, L.L.C.¶R¶i83,259ªÑ 4. XTX TOPCO LTD¶R¶i27,666ªÑ 5. JANE STREET GROUP, LLC¶R¶i23,093ªÑ 6. ONYX BRIDGE WEALTH GROUP LLC¶R¶i22,727ªÑ
¤Wz6®a³£¬O²Ä¤@¦¸¶R¶i¡A¶R¶iªº»ù¦ì³£¬O1.2¤¸/ªÑ¡A³o»ò¥© (¦U¦ì¥i¥H¥h¬d¥L̪ºt³d¤H) ¨È·à±d¤£¬O¼öªùªÑ§a(¼öªùªÑ§Ú´N¬Û«H¬O¥©¦X) (´N¥ý¥H¤º½u¸ÑŪ)
¨ä¤¤·ç»È113/2/6¦A¥[½X¶R¶i16,292,600ªÑ
¸ò¦U¦ì¤À¨É³oÓ´¡¦± (§ë¸ê·ÀI½Ð¦Û¦æµû¦ô)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/2/17 ¤U¤È 03:17:52
²Ä 6551 ½g¦^À³
|
1.Dupilumabªº¦¨ÁZ¦³¥Ø¦@¸@¡A§âEblasakimab®³¨Ó¤ñ¸û¡A·íµM¬Ý°_¨Ó«e³~¤@ ¤ù¥ú©ú¡A¦pªG¯uªº¯à¸òDupilumab¤À®x§Ü§¡A¨º¦Ñ·à¤ÍÌ´N¦³ºÖ¤F¡A¦ý¤ñ°_ ¸òDupilumab¬Û¤ñ¡AASLAN¥Ø«eªºª¬ªp§ÚˬOı±o¸òCNTB¤ñ¸û¬Ûªñ¡A¤@¼Ë¬O ¬D¾ÔDupilumab¡A¦ý¤G´Á¸ÕÅçµ²ªG³£¦]¦w¼¢¾¯²Õ¤ÏÀ³²v¤]°ª¡A»P¹êÅç²ÕÀø®Ä ®t²§¨S¦³·Q¹³¤¤¤j¡A¾ÉPªÑ»ù§C°g¤£®¶¡AASLAN¸òCNTB¤]³£ÁnºÙ¦¸±Ú¸s¤ÀªR ªí¥ÜAD¸û¬°ÄY«ªÌ¡A¦w¼¢¾¯²Õ»P¹êÅç²Õ®t¶Z§¡¦³®Ä´£°ª¡ACNTBªºCBP-201±q 2022¦~¤G´Á¸Ñª¼µ²§ô¨ì²{¦b³£¥¼Äw¨ì¤T´Á¸êª÷¡A2023¦~11¤ëµo¥¬CBP-201©µ ¦ù¨ì52¶gªºªvÀøµ²ªG¡A즳16¶g¦³®Ä±wªÌ«ùÄòªvÀø¨ì52¶g«á¬ù¦³8.9¦¨¯àºû «ùÀø®Ä¡AµM«áñq±ÂÅv¦X¬ù¡A¦¬¨ú«eª÷¤j¬ùUSD2100¸U¡AÁ`±ÂÅvª÷¬ù USD1.25»õ¡A²{¦bAD¤T´Á¤]¬OÄw¤£¨ì¸êª÷¿ð¿ðµLªk¶}©l¡A¶ZÂ÷¸Ñª¼¦Ü¤µ¤w ¹L1¦~¥H¤W¡A¥u¯à´Âý³Ý¥tÅP³~®|¡A¤£Ä±±o³o¸òASLAN¤ñ¸û±µªñ?¶Z¸Ñª¼¦Ü¤µ ¤]¤w¹L¤F¤j¥b¦~¡ATREK-DX¹wp¦³µ²ªG¤]¬O2024¦~©³¤F.......
2.³o¤@ªi°h³õªºªÑªFÌ°£¤FTANG¡A²H°¨¿üµ¥µ¥¸û¦´ÁªºªÑªF¤]³£¤@°_ºM¤F ¡AÁöµM«ùªÑ³°Äò¦³ªk¤H±µ¤â¡A¦ý©Ò¿×ªº¤º½uÃø¹D¨¬°³Ì¤jªÑªFªºTANG¤]¤£ ª¾¹D¡A¼ÝµM¨MµM¥X°â¤j¶q«ùªÑ?³o§Ú«ù«O¯dºA«×¡A¤£¹L¦³¤HªÖ±µªº½T¤]¬O¦n ¨Æ¤@¼Î¡C
3.²{¦b°ò¥»¤W´N¬O¤@½¤GÀü²´¡A¼ÖÆ[ªÌı±o¤ñªÓDupilumab¡A´dÆ[ªÌı±o¸ò CBP-201®t¤£¤F¦h¤Ö¡AÁ`¤§°µ¦n¤ß²z·Ç³Æ§Y¥i¡AŤ§§Ú©¯¡A¿é¤§§Ú©R¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/17 ¤W¤È 10:02:52
²Ä 6550 ½g¦^À³
|
(·s¼W§ùÁת¢2023¦~¾P°âÃB)
¨È·à±d¨ÖÁʪ÷ÃBºâªk¦p¤U¡G °Ñ¦Ò·|û¡G¤Ñ©R¤j10141925 µoªí®É¶¡:2023/6/22 ¤U¤È 08:20:52 ASLAN004 ¥þ²y±ÂÅv+§Q¼í¤§¹w¦ô ¤é¥»¦û¥þ²y¾P°â¬ù5%.,±ÂÅvª÷1.385 »õ¬ü¤¸. ¥þ²y±ÂÅvª÷¦ô 1.385/5%=27.7»õ¬ü¤¸ 27.7-7.8(CSL¦¨¥»)=19.9»õ¬ü¤¸(¦©°£CSL¦¨¥»¤§§Q¯q) ASLN004 ¤§»ùÈ:¥þ²y±ÂÅvª÷ 19.9»õ¬ü¤¸ + 10% ¾P°â¤À¼í ¾P°â¤À¼í: 20%- 10%=10%(¦©°£CSL¦¨¥»¤§§Q¯q) ¥H¤W¥¼§t003°Ó¥Î«á¤§¨ÖÁÊ»ù¡C ¥[003°Ó¥Î«á¤§¨ÖÁÊ»ù¦ô¬ù¬üª÷25»õ¤¸³Q¨ÖÁÊ(©¹«áªº20¦~¡C¨C¤@¦~ªº10% ¾P°â¤À¼í¥¼ºâ¶i¥h)¡C
¥tÃö©ó¾P°â¤À¼í¨C¦~10%¡G ¥H§ùÁת¢2023¦~Á`¾P°âÃB115.9»õpºâ¡A ·sÃĤò§Q¥H8¦¨pºâ¡G115.9*0.8=92.72»õ¬ü¤¸¬OÁÉ¿Õµá³æ³æ2023¦~½æ§ùÁת¢²bÁÈÈ 115.9*10%=11.59»õ¬ü¤¸´N¬O·í(¥h)¦~¾P°â¤À¼í10%ªºÈ
§ùÁת¢¦~«×¾P¦¬ª÷ÃB¦p¤U¡G(·PÁ¤ѩR¤j´£¨Ñ) 2017¦~/2.279»õ¬ü¤¸ 2018¦~/9.22»õ¬ü¤¸ 2019¦~/23.156»õ¬ü¤¸ 2020¦~/40.448»õ¬ü¤¸ 2021¦~/61.988»õ¬ü¤¸ 2022¦~/86.811»õ¬ü¤¸ 2023¦~/115.9»õ¬ü¤¸ §ùÁת¢¦Ü2023¦~¤î¦@¾P°â339.8»õ¬ü¤¸ ¾P°â¤À¼í10%=33.98»õ¬ü¤¸(´«ºâ¾P°â¤À¼í15¦~§Y¶W¹L150»õ)( Eblasakimab¦p¥xÁÞ¤j©Ò»¡ªGµM¬O¶W¯Å¤jÃÄ)
ASLN ¦¨¾À¯È¾÷²v¬Û·í§C¡D ¦ý¶W°ªÀø®Ä¤£¥i¯à¡D ¥unÀø®Ä¡B¥ÎÃÄÀW²vĹ¹L§ùÁת¢§Y¥i
Eblasakimab¦b©¹«á20¦~ªº¾P°â¹w¦ôȤ@©w°Ñ¦Ò§ùÁת¢q©w ³o20¦~ªº¾P°â¤À¼í¥[Á`(¾P°â¤À¼í¨C¦~10%)¤]·|¨Ö¤J¨È·à±d³Q¨Öª÷ÃB¸Ì±¡C
(¥H¤W³¡¤À¯ÂÄÝÁr´ú¡BÁr´ú¦p¦³¹p¦P¡B¹êÄÝ¥©¦X) ¥H¤W½Ð«ü¥¿ (§ë¸ê¦³·ÀI¡B½Ð¦Ût¬ÕÁ«)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/16 ¤U¤È 05:09:19
²Ä 6549 ½g¦^À³
|
·PÁ¸ó±i¤j
¦pªG¬O³o¼Ëªº¸Ü
Aslan ÁÙ¦³À¸
§Æ±æ ±µ¤U¨Ó ¦nÀ¸³s¥x |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/16 ¤U¤È 04:38:48
²Ä 6548 ½g¦^À³
|
½Ð¬d¥H¤Uºô¯¸ whalewisdom.com/stock/asln (½Ð°O¤U¨Ó¡A113/5/15ÁÙ·|¦A¬d¤@¦¸)
112/12/31¤î «ùªÑ²Ä1¦WBVF ·s¼W«ùªÑ34,856,975ªÑ¨Ó¨ì43,344,975ªÑ «ùªÑ²Ä2¦WK2 ·s¼W«ùªÑ17,174,449ªÑ¨Ó¨ì22,467,675ªÑ «ùªÑ²Ä3¦W·ç»È ·s¼W«ùªÑ16,292,600ªÑ¨Ó¨ì16,917,600ªÑ
𤽥q´î«ù39,020,205ªÑ³Ñ6,134,975ªÑ ð¸ê¥»¥X²M1,901,552ªÑ
(ªoºj·Æ±¼¤j¤j¦b2024/1/3 ¤W¤È 10:36¦³µoªí¤F) (§Ú¬Q¤Ñ¥u·Q½T»{¬y¦V¡A¦]¬°¶q¤j¡An¦³¤H¥i¥H±µ¤U¨Ó¡Cì¨Ó¬OBVF¡BK2±µ¨«)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªL®õ10030886 |
µoªí®É¶¡:2024/2/16 ¤U¤È 02:33:39
²Ä 6547 ½g¦^À³
|
¬O¦b»¡¹Ú¸Ü¶Ü¡H
½Ð°Ý¸ó±i¤j ðªºÄw½X³Q³o¨â®a±µ¨«ªº¸ê®Æ þ¸Ì§ä±o¨ì¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/16 ¤U¤È 12:40:16
²Ä 6546 ½g¦^À³
|
¬Q±ß(2/15)ªº½L§ó©úÅã ¨C¹j¬ù10¤ÀÄÁ¥æ©ö900~1000ªÑ ¥D¤O¦b¸Ì±
¥t 𤽥qªºÄw½X¥þ³QBVF¡BK2±µ¨« BVF¡BK2¬O¥h¦~2¤ëªº¶U´Ú»È¦æ (ª¾¹D¨È·à±d·|Ë¡AÁÙ¶U´Úµ¹¥¦¡AÁÙ±µ¥¦ªºªÑ²¼???) (ÁÙ´ÚÁÙ®i©µ¨ì114¦~1¤ë1¤é)
¥t ¤µ¦~2/1~2/13¤Î2/15ªº½L¤¤¥æ©ö¹ï¶H ¦]Äݤµ¦~Q1¡An¤µ¦~5¤ë15¤é¤~·|ª¾¹D ½L¤¤¥æ©ö¹ï¶H¤~¬O«ÂI ¦]¨È·à±d³Q¨Öªº¤º³¡¸ê°T¤w¸g©ú®Ô ³o´N¬O¤º½u
5¤ë15¤é«e³Q¨Ö¾÷·|¤j ³Q¨Ö«á µ¥¨ì5/15§ÚÌ´Nª¾¹D¤µ¦~2/1~2/13¤Î2/15ªº½L¤¤¥æ©ö¹ï¶H¬O½Ö¤F ³o´N¬O¤º½u
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2024/2/14 ¤U¤È 11:06:17
²Ä 6545 ½g¦^À³
|
2/1~2/13(¬Q¤Ñ),¨C¤ÀÄÁ³£¦³¦¨¥æ°O¿ý,¬O¤£¥¿±`ªº¡C¥u¯àÃÒ©ú¦³¥D¤O¦bùر¡C
²{¦b(2/14), 10:30(¶}½L)¦¨¥æ134ªÑ 10:42¦¨¥æ6000ªÑ 10:45¦¨¥æ100ªÑ 10:46~11:00¨S¦¨¥æ¶q¡C ¤µ¤Ñ½L¶Õ«ì´_¥¿±`(¨S¦³¨C¤ÀÄÁ³£¦³¦¨¥æ¶q)¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/2/9 ¤U¤È 10:44:14
²Ä 6544 ½g¦^À³
|
´N½u½×½u ªñ´Á©³³¡¥X¶q¡A¶}§C¨«°ª¦h¤é¯dªø¤U¼v½u¡A ¤ë½u¦¤w¬ð¯}©u½u½u§e²{¤¤´Á¦hÀY±Æ¦C¡A¤µ¤é¦A¶}§C¨«°ª ¤Q¤é½u±N¬ð¯}¤ë½u¡Aµu´Á¦hÀY±Æ¦C§Î¦¨¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/2/9 ¤W¤È 10:06:18
²Ä 6543 ½g¦^À³
|
·Pı¦³¤H³s3¤Ñ¦b0.55ªþªñ¦Y³f¡A
ªÑ»ù¤w¸gÄê«Ü¦h¦~¤F¡A
§Æ±æ¯àÀs¦~·s¦~·s®ð¶H¡A
¯¬ºÖ¤j®a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/2/8 ¤W¤È 12:14:35
²Ä 6542 ½g¦^À³
|
¤S½M¤SÄê §j³£¤£·| ªÑ»ù¤]¼µ¤£°_¨Ó=_= |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gblessyiche10143957 |
µoªí®É¶¡:2024/1/19 ¤U¤È 11:58:58
²Ä 6541 ½g¦^À³
|
½Ð°ÝFirstrade «ç»ò²{¦b¤£¯à¶R¡A¥u¯à½æ°Ú¡H ¥X²{¡¨¡¨Illiquid,Opening Position Trades Not Accepted ¡¨ »Ýnñ¸p¤°»ò¸ê®Æ¶Ü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2024/1/17 ¤W¤È 11:39:26
²Ä 6540 ½g¦^À³
|
¬Q¤Ñ©M¥h¦~7¤ë6¤éII´Á¸Ñª¼«®À¤@¼Ë¡A
¤U¶^ªñ4¦¨¡A¤S±N¶}±Òªø´Á¤U¶^ÁͶաA
½Ð°Ý¦U¦ì¤j¤j¡A
¹wq1¤ë24¤éªÑªF·|±ÂÅv¤½¥q¸ê¥»¼W¥[¡A
¬O¤£¬O¦³¤H¤£·Q°Ñ¥[¥ý¨«¡A©Î¬Oµu´ÁÀò§Q¤Fµ²¡A
·Pı³oªÑ¦h¨a¦hÃø¡A±q¥¼À°ªÑªF¿Ñ¤@ÂIÂIçħQ¡A
¤Ñ©R¤j±zªº¬Ýªk©O
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/16 ¤U¤È 09:14:11
²Ä 6539 ½g¦^À³
|
·íAslan pharmaceutical ADR ¹L¤F1¬ü¤¸¡A¤U¥«ºÃ¼{¸Ñ°£¡A´N¬O²¢»e»ùªº¶}©l¡A°²¦p§ë¸ê¾÷ºcµû¦ô¤½¥q¦³16¬ü¤¸¡A¶V±ß¦^¸É²¢»e«×¶V§C,¶V¦¦^¸É²¢»e«×¶V°ª¡A§C»ù´N¬O³Ì¤jªº»¤¦]¡C ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ²`¤Jµû¦ô ¦A°µ¨Mµ¦
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/1/12 ¤U¤È 11:43:30
²Ä 6538 ½g¦^À³
|
¤w¸g0.86 §CÂI¹L¤F¶R¤£¨ì²¢²¢»ù¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/12 ¤U¤È 09:04:41
²Ä 6537 ½g¦^À³
|
³¡¥÷§ë¸ê¾÷ºc°ªÂI½æ¥X«ùªÑ,À£§CÀ~¥XÄw½X,¥Ø«e²{ª÷º¡º¡¥i¥H±q§CÂI¦^¸É,¤]¥i¥H»{ªÑÂX¤j«ùªÑ¤ñ²v «ç»ò¤U¨Ó«ç»ò¤W¥h, «ùªÑ¦¨¥»°ª¨S¦³½æ¥X©Î¤w½æ¥X¦³»ù®t, ¦pªG¦Û¤vµû¦ô¥Ø«e¤½¥q¬ãµoÃĪ«¦³¼ç¤O¡A ¨S¦³·Q¹³ªº¨º»ò®t,±©¤@ªº«Øij°Ê§@´N¬O¶q¤O¦Ó¬°ºÉ§Ö¦^¸É,¤p¿ú¤jÅu¥,§Ö³t°§C¦¨¥»
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/1/12 ¤U¤È 08:20:32
²Ä 6536 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/1/11 ¤W¤È 03:13:56
²Ä 6535 ½g¦^À³
|
¯u¤û¹G ©³³¡¤û¥« ¤S¤jº¦20% ¿ð¿ð¤£´±¥[½X¤@ª½¦b¬ÝÀ¸ n¦^¥»¤]¦nÃø |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/9 ¤U¤È 06:43:30
²Ä 6534 ½g¦^À³
|
Eblasakimab ¦bºC©Êªý¶ë©ÊªÍ¯fCOPD ªº¼ç¤O (¥þ²yCOPD¥«³õ 2022¦~181»õ¬ü¤¸ ¹w´Á¨ì 2032¦~¹F298.8»õ¬ü¤¸)
Eblasakimab¬O¤@ºØ·s«¬¥þ¤H·½³æ®è IgG4 §ÜÅé¡A¥i¯S²§©Êµ²¦X¥Õ¦å²y¤¶¯À (IL)-13 ¨üÅé (IL-13R)¡Aªý¤î³z¹L 2 «¬¨üÅé¶Ç»¼ IL-4 ©M IL-13 °T¸¹¡C 2«¬¨üÅé¬O¥]§tIL-4¨üÅé(IL-4R)©MIL-13¨üÅé(IL-13R)ªº²§¤G»EÅé¡C²ÓM¿E¯À IL-4 ©M IL-13 ³z¹L 2 «¬¨üÅéµo¥X°T¸¹¡A¬Oµoª¢ªºÃöÁäÅX°Ê¦]¯À¡A¬O¤Þµo AD¡B®ð³Ý©M COPD µ¥ 2 «¬¯e¯fªº¹L±Ó¯gª¬ªºÃöÁä¡C
Dupilumab ¬O¤@ºØ¥þ¤H·½³æ®è§ÜÅé¡A¥iªýÂ_¥Õ²ÓM¤¶¯À 4 ©M¥Õ²ÓM¤¶¯À 13 ªº¦@¨É¨üÅ馨¤À¡A¥Õ²ÓM¤¶¯À 4 ©M¥Õ²ÓM¤¶¯À 13 ¬O 2 «¬µoª¢ªºÃöÁäÅX°Ê¦]¯À¡C
Dupilumab¥h¦~°ò©ó BOREAS ªº¥¿±µ²ªG¡AFDA ±Â¤© Dupixent ¬ð¯}©ÊÀøªk»{©w¡A§@¬°¥¼¨ü±±¨îªº COPD ¦¨¦~±wªÌªºªþ¥[ºû«ùªvÀø¡A³o¨Ç±wªÌ¦³¥[«¥v©M¶Ý»Ä©Ê²É²ÓMªí«¬¡CFDA ®Ú¾Ú¸Ó¸ÕÅ窺¼Æ¾Ú±Â¤© Dupixent ªvÀøºC©Êªý¶ë©ÊªÍ¯fªº¬ð¯}©ÊÀøªkºÙ¸¹¡C ¼Ú¬wÃÄ«~ºÞ²z§½¤w¸g¦b¼f¬d Dupixent §@¬°ªvÀø¥¼¨ü±±¨îªº±w¦³ 2 «¬µoª¢ªº COPD ±wªÌªºÃĪ«¡C
Dupixent 3 ´Á¸ÕÅçÁ{§É¼Æ¾Ú Dupixent ¦b²Ä¤G¶µ¿n·¥ªº 3 ´Á¸ÕÅ礤ÅãµÛ´î¤Ö¤F COPD ´c¤Æ¡A¥[³t¤F FDA ªº´£¥æ¨Ã½T»{¤F¦¨¬°²Ä¤@Ó§åã¥Î©óªvÀø³oºØÄY«¯e¯fªº¥Íª«»s¾¯ªº¼ç¤O NOTUS ¸ÕÅç¥HÀ£Ë©ÊªºÀø®Ä¹F¨ì¤F¥Dn²×ÂI¡AÅã¥Ü¦b¦³2 «¬µoª¢ÃÒ¾Ú¡]§Y¦å²G¶Ý»Ä©Ê²É²ÓM≥300 Ó²ÓM/£gL¡^ªº¤¤««×COPD ±wªÌ¤¤¡A»P¦w¼¢¾¯¬Û¤ñ¡ADupixent ÅãµÛ°§C¤F34% ªº¯f±¡¥[«¡AÃÒ¹ê¤Fµ²ªG¨Ó¦Û¨ã¦³¨½µ{¸O·N¸qªº BOREAS ÃöÁä¸ÕÅç¦b²Ä 12 ¶g®É¡A»P¦w¼¢¾¯¡]FEV 1¬° 57 mL¡^¬Û¤ñ¡ADupixent ¨³³tÅãµÛ§ïµ½¤FªÍ¥\¯à¡] FEV 1¬° 139 mL¡^ p¹º©ó 2023 ¦~©³´£¥æ¸É¥R BLA ¥ú¬O¦b¬ü°ê´N¦³¬ù 30 ¸U¤H±w¦³¤£¨ü±±¨îªººC©Êªý¶ë©ÊªÍ¯f¡A¨Ã¦³ 2 «¬µoª¢ªºÃÒ¾Ú¡F¤Q¦h¦~¨Ó¨S¦³·sªºªvÀø¤èªkÀò±o§åã
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2024/1/9 ¤W¤È 01:07:44
²Ä 6533 ½g¦^À³
|
³Ìªñ0.4¥ª¥k «Ü®e©ö´N©Ô1¸ò10´X% ´N½u½×½uªº¸Ü 0.58 ÀV½u¹L¥h¤j®a·|¨ÓÉu¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/1/8 ¤U¤È 04:03:08
²Ä 6532 ½g¦^À³
|
¥¼¨Ó®i±æ¦pªG¯uªºÀu¨q¡A³Ì¤jªÑªF¦ó¥H¤j½æ¤â¤¤«ùªÑ?Ãø¤£¦¨TANG CAPITAL¤ñ¦U¦ìÁÙ¤£²M·¡ASLAN?TANG CAPITAL¤]¬O«ù¦³¤F ¤@¬q®É¶¡¡A¬°¦ó¿ï¦b¥¼¨Ó¤j¨Æ¥óµo¥Í«e½æªÑ?¤ñ°_2.3¤ë¥Ó³ø2023/12«ùªÑ¤~µo²{¤jªÑªF¶]¤F¡A²{¦bSEC¤å¥ó¤w¸g´¦ÅS¤F¡A¤£¥Î µ¥¨ìTANG CAPITAL¥Ó³ø«ùªÑ´Nª¾¹D¤w¸g½æ¥ú쥻«ù¦³ADS¡A¥h½½Â¤å´N¥i¥Hª¾¹D¬Y¨Ç¯S©w¤H¤h¦h·R´£TANG CAPITAL¦h¤j©@ ¡A«ùÄò¥[½X«ùªÑ¡A¤S¬O¤jªÑªF¤S¬OSurveyor¡Aµ²ªGTANG CAPITAL¤w¸g¥X²MADS¡A«o¤£·í¤@¦^¤l¨Æ¡AÁ`¤§¤jªÑªF¥X²æ«ùªÑ¬OÓ Äµ°T¡AYÁÙ«ù¦³ªº·à¤Í¤]¤£«Øij½æ¤F¡A¥Ø«e»ù®æ»P¨ä³B¤À¡AÁÙ¤£¦p©ñµÛµ¥«Ý©_ÂÝ¡A¦ýY¬O·Qn¥[½XÅu¥½Ð¤T«ä¡A²¦³º¯uªº©_ Âݵo¥Í¡A즳«ùªÑ¥»´N²zÀ³¦³Àò§Q¡A¦ý¦pªG¤£¦p¹w´Áªº¸Ü¡A¬ü³W¾À¯È¤£µL¥i¯à....... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2024/1/3 ¤U¤È 10:23:41
²Ä 6531 ½g¦^À³
|
¤µ¦~·|µo§GCOPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅç¶i¤@¨B¼Æ¾Ú ºë±K¤Á³ÎªÍ¤Á¤ù (PCLS) ¤¤ÀY¹ïÀY¤ñ¸ûªº·sªº¡B¦³§Æ±æªº¼Æ¾Úªí©úeblasakimab ¤ñ dupilumab ¨ã¦³´£°ªÀø®Äªº¼ç¤O
¤°»ò¬OÀY¹ïÀY¬ã¨s( Head to Head study)
¬O¨Ï¥Î¤w¸g¦b¨Ï¥ÎªºªvÀøÃĪ«§@爲ª½±µ¹ï·Ó²Õ¡A¥iµø爲¨âºØÃĪ«ªºª½²y¹ï¨M, ª½±µPK( ¬ã¨sÃĪ«»P¨Ï¥Î¤¤ªºªvÀøÃÄ) ¡C°w¹ïÃĪ«ªºÀø®Ä»P¦w¥þ©Ê¶i¦æ§óª½±µªºPK ¡A¥HÁקKÂùª¼¸ÕÅç®É¯f±w©â¨ì¦w¼¢¾¯²Õ¦Ó¼vÅT¯f±¡ ¬OÄÝ©ó¤ñ¸û²Å¦X¤H¹DªºÁ{§É¸ÕÅç³]p, Head to Head study ³]p¥¼¨Ó·|¶V¨Ó¶V¨ü¨ì«µø»P±Ä¥Î
Âà¤Æ¤u§@ÃÒ©ú¤F eblasakimab ¦b COPD ¤¤ªº¼ç¤O¡AÀY¹ïÀY¼Æ¾Úªí©ú¨ä¥i¯àÀu©ó dupilumab¡A¤ä«ù eblasakimab ¸Ñ¨M¼sªxªº AD ¦@¨Ö¯gªº¼ç¤O¡C¥O¤H¿³¾Äªº¬O¡A¦b¨Ï¥Î¤HÃþ COPD ªÍ¼Ò«¬ªºÀY¹ïÀY¹êÅ礤¡A§ÚÌÆ[¹î¨ì eblasakimab ¤ñ dupilumab ¨ã¦³§ó±jªº®ÄªG¡A§ÚÌ´Á«Ý©ú¦~µo¥¬³o¨Ç¬ã¨sªº¶i¤@¨B¼Æ¾Ú¡C
New, promising data of head-to-head comparison in PCLS suggests eblasakimab has potential for improved efficacy over dupilumab ( 2024 ¦~1¤ë ²³øP18)
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2024/1/3 ¤W¤È 10:36:42
²Ä 6530 ½g¦^À³
|
¦³½ìªº¨Æ±¡¨Ó¤F.....
1.2023/7/11ªºSEC¤å¥óÅã¥Ü¡ATANG CAPITAL«ù¦³180.6¸UªÑADS + 5ªÑì©lªÑ(0.2ªÑADS)¡C
2.ºI¦Ü2023/9/30¡ATANG CAPITAL¥Ó³ø«ù¦³aslan190.16¸UªÑads¡A«ùªÑ¬ù11.41%¡C
3.2024/1/2ªºSEC¤å¥óÅã¥Ü¡ATANG CAPITAL¥X²M©Ò¦³ADS¡A¶È³Ñ«ù¦³5ªÑì©lªÑ + °õ¦æ»{ÁÊÅvªº6,134,970ªÑì©lªÑ¡A ¦Xp¬ù245,399ªÑADS¡A«ùªÑ¬ù1.5%¡C(¾ÚSEC¤å¥ó´¦ÅS¡A°õ¦æ»{ªÑÅv«á«ùªÑ¶W¹L9.99%¡A«h»{ªÑÅvµLªk°õ¦æ¡A¤£ª¾¹DTANG CAPITAL¬O§_¬°¤F°õ¦æ»{ªÑÅv½æ¥X«ùªÑ¡A¦ý¥þ³¡¥X²M¤S»{ªÑ¡A§Ú¬Oı±o¦³ÂI¥Ù¬Þ...)¡C
2023/9/30ªÑ»ùÁÙ¦³1.8ªþªñ¡A±q10¤ë¶}©l¤@¸ô±Y¶^¡A¬Ý¨ÓÀ³¸Ó¤j·§²v¬OTANG CAPITAL¥X²M190.16¸UªÑADSªº½t¬G¡AÁ`¤§´N¬O¨Æ¹ê³¯z¤F¡A«ç»ò¸ÑŪ´N¬Ý¦U¦ì·à¤Í¤F.......
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2024/1/2 ¤U¤È 08:38:54
²Ä 6529 ½g¦^À³
|
覬¨ì·à¤lªºmail n¶}§ë¸êªÌ·|ij ¸Ó¤£·|¦³¤°»ò®ø®§ ¦³ÂI·Q¶R¦^«ùªÑ½ä¤@¤U¡]Äo¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/12/29 ¤U¤È 04:41:15
²Ä 6528 ½g¦^À³
|
¤£¥Îµe¥¼¨Ó¤j»æ
©ú¦~TREK-DX ¸ÕÅç¡A¦p¥¼¹F²ÎpÅãµÛ®ÄªG
°¨¤W´N¤@¤M²¦©R |
|
¡@ |
¦^°Q½×°Ï1¶ |
³Ì·s100«h¦^ÂÐ >> |